iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases.
paper
Cited
Public
- Authors
- Abud, Edsel M; Ramirez, Ricardo N; Martinez, Eric S; Healy, Luke M; Nguyen, Cecilia H H; Newman, Sean A; Yeromin, Andriy V; Scarfone, Vanessa M; Marsh, Samuel E; Fimbres, Cristhian; Caraway, Chad A; Fote, Gianna M; Madany, Abdullah M; Agrawal, Anshu; Kayed, Rakez; Gylys, Karen H; Cahalan, Michael D; Cummings, Brian J; Antel, Jack P; Mortazavi, Ali; Carson, Monica J; Poon, Wayne W; Blurton-Jones, Mathew
- Year
- 2017
- Journal
- Neuron
- PMID
- 28426964
- DOI
- 10.1016/j.neuron.2017.03.042
- PMCID
- PMC5482419
Microglia play critical roles in brain development, homeostasis, and neurological disorders. Here, we report that human microglial-like cells (iMGLs) can be differentiated from iPSCs to study their function in neurological diseases, like Alzheimer's disease (AD). We find that iMGLs develop in vitro similarly to microglia in vivo, and whole-transcriptome analysis demonstrates that they are highly similar to cultured adult and fetal human microglia. Functional assessment of iMGLs reveals that they secrete cytokines in response to inflammatory stimuli, migrate and undergo calcium transients, and robustly phagocytose CNS substrates. iMGLs were used to examine the effects of Aβ fibrils and brain-derived tau oligomers on AD-related gene expression and to interrogate mechanisms involved in synaptic pruning. Furthermore, iMGLs transplanted into transgenic mice and human brain organoids resemble microglia in vivo. Together, these findings demonstrate that iMGLs can be used to study microglial function, providing important new insight into human neurological disease.
Differentiation of human iPSC derived microglia like cells (iMGLs)(A) Schematic of fully-defined iMGL differentiation protocol. (i) Human iPSCs are differentiated to CD43+ iHPCs for 10 days and then cultured in serum-free microglia differentiation media containing human recombinant MCSF, IL-34, and TGFβ-1. Differentiation is carried out for an additional 25 days after which iMGLs are exposed to human recombinant CD200 and CX3CL1 for 3 days. (ii) Representative image of iHPCs in cell culture at day 10. Scale bar = 100 μm. (iii) By day 14, iMGLs express PU.1 (green) and TREM2 (red). Scale bar = 50 μm. (iv) Representative phase contrast image of iMGL at day 38. (B) Schematic of differentiation of iPSCs to iHPCs. (i) Single-cell iPSCs are differentiated in a chemically defined media supplemented with hematopoietic differentiation factors and using 5% O2 (4 days) and 20% O2 (6 days). (ii) After 10 days, CD43+ iHPCs are CD235a+/CD41a+(C) iMGLs develop from CD45+/CX3CR1− (A1) and CD45+/CX3CR1+ (A2) progenitors. (D) CD45 fluorescence intensity shows that iMGLs (blue) maintain their CD45lo-int profile when compared to monocyte-derived macrophages (MD-Mφ). (E) iMGL progenitors are CD11blo and increase their CD11b expression as they mature. At 14 DIV, a small population (~11%) cells with CD11bint-hi are detected. (F) CD11b fluorescence intensity demonstrates that CD11b expression increases as iMGLs age, resembling murine microglial progenitors identified by Kierdorf, et al 2013. (G) Mary-Grunwald Giemsa stain of monocytes, MD-Mφ, fetal microglia, and iMGLs. Both fetal microglia and iMGL exhibit a high nucleus to cytoplasm morphology compared to monocytes and MD-Mφ. Scale bars = 16 μm. (H) iMGLs also exhibit extended processes and express CX3CR1 (green) together with the human cytoplasmic marker (hCyto, SC121; red). (I) Differentiation yields >97.2% purity as assessed by co-localization of microglial-enriched protein P2RY12 (green), microglial-enriched TREM2 (red) and nuclei (blue (n=5 representative lines). See also Figures S1 and S2.
iMGL transcriptome profile is highly similar to human adult and fetal microglia(A) 3D Principal Component Analysis (PCA) of iMGLs (blue), human adult microglia (Adult MG; green), human fetal microglia (Fetal MG; beige), CD14+/CD16− monocytes (CD14 M; pink), CD14+/16+ monocytes (CD16 M; maroon), blood dendritic cells (Blood DC; purple), iHPCs (red), and iPSCs (yellow) (FPKM ≥ 1, n=23,580 genes). PCA analysis reveals that iMGL cluster with Adult and Fetal MG and not with other myeloid cells. PC1 (21.3% var) reflects the time-series of iPSC differentiation to iHPC (yellow arrow) and then to iMGLs (blue arrow). PC2 (15.4% var) reflects the trajectory to Blood DCs. PC3 (7.6% var) reflects the trajectory to monocytes (B) Heatmap and biclustering (Euclidean-distance) on 300 microglia, myeloid, and other immune related genes (Butovsky et al., 2014; Hickman et al., 2013; Zhang et al., 2014). A pseudo-count was used for FPKM values (FPKM +1), log2-transformed and each gene was normalized in their respective row (n=300). Representative profiles are shown for genes up and down regulated in both human microglia (fetal/adult) and iMGLs. (C) Bar graphs of microglial-specific or –enriched genes measured in iMGL, Fetal and Adult MG, Blood DC, CD14 M, and CD16 M as [Log2 (FPKM +1)] presented as mean ± SEM. Data was analyzed using one-way ANOVA followed by Tukey’s corrected multiple comparison post hoc test. Statistical annotation represents greatest p-value for iMGL, Fetal MG, and Adult MG to other myeloid cells. CD14 M (n=5, CD16 M (n=4), Blood DC (n=3), iMGL (n=6), Fetal MG (n=3), and Adult MG (n=3). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Complete statistical comparisons are provided in Table S1. See also Figures S2 and S3.
iMGLs are physiologically functional and can secrete cytokines, respond to ADP, and phagocytose human synpatosomes(A–B) By flow cytometry analysis, iMGL (blue) are CD45lo-int similar to fetal MG (orange) but different from CD45hi MD-Mφ (fuchsia). (B) Histogram of CD11b intensity (left) reveals that Fetal MG express slightly more CD11b than iMGL but less than MD-Mφ. (C) iMGLs secrete cytokines and chemokines when stimulated for 24 hours with either IFNγ (20 ng/ml), IL-1β (20 ng/ml), or LPS (100 ng/ml) by ELISA multiplex. (D) ADP (100 μM) induces iMGL migration in a trans-well chamber (5 μm). Pre-exposure to the P2ry12 antagonist, PSB0739 (50 μM, 1 hr) completely abrogates ADP-induced iMGL migration (***p<0.0001). (E) ADP induces calcium flux in iMGLs via P2ry12 receptors. (Left) Exposure to ADP leads to elevated calcium influx (I340/I380 ratio) in vehicle group (green trace) but not in PSB0739-treated group (black trace). (Right) Representative images of ADP-induced calcium flux at 240 s in vehicle (top) and PSB0739 (bottom). (F) iMGLs phagocytose human brain-derived synaptosomes (hS). Representative images captured on Amnis Imagestream display phagocytosis of hS by MD-Mφ and iMGLs. (G) Quantification of phagocytosis shows that iMGLs internalize hS at 50% of macrophage capacity (p<0.0001). (H) Representative images of iMGL phagocytosis of hS in the presence of either a Mertk inhibitor UNC569 (top) or anti-CD11b antibody (bottom). (I; top) iMGL phagocytosis of hS phagocytosis is reduced byby approximately 12% (burgundy bar, p<0.05) by blocking Mertk, but 40% (p<0.0001, green bar) by inhibiting CR3 via CD11b blockade. (I; bottom) Sub-analysis of iMGLs exhibiting a phagocytic event reveals similar average amounts of internalization across treatment groups (p=0.1165). All histograms reported as mean ± SEM. Cytokine and migration assays one-way ANOVA, followed by Dunnett’s multiple-comparison post-hoc test, ***p<0.0001, **p<0.001, *p<0.05; Cytokine assay: n=3 wells/group. Migration Assay: n=5 fields/condition. Calcium assay: vehicle (n=37 cells), PSB0739-treated (n=17 cells), I340/I380 represented as mean ± SEM at each time point. Phagocytosis assay: MD-Mφ vs iMGL: Unpaired t-test, **p<0.001, n=3 wells/group. MERTK and CR3 assay, one-way ANOVA, followed by Tukey’s multiple-comparison post-hoc test, ***p<0.0001; n= 6 for vehicle, n=3 wells/group. See also Figure S4.
Alzheimer Disease risk factor GWAS genes can be investigated using iMGLs and high throughput genomic and functional assays(A). Heatmap of 25 immune genes with variants associated with LOAD reveals that major risk factors APOE and TREM2 are highly expressed in iMGLs, Adult MG, and Fetal MG. (B) iMGLs internalize fluorescent-labeled fAβ and pHrodo-dye BDTO. Representative images captured on Amnis Image StreamX Mark II. (C) iMGLs were exposed to unlabeled fAβ (5 μg-ml−1) and BDTOs (5 μg/ml) for 24 h and mRNA expression of 19 GWAS genes was assessed via qPCR array. fAβ treatment elevated the expression of 10 genes above 2-fold compared to vehicle, including MS4A6A (6.3 fold), CD33 (6.1 fold), ABCA7 (5.8 fold), TYROBP (4.98) and TREM2 (4.85 fold). Whereas, BDTO exposure elevated the expression of 4 genes above two-fold compared to vehicle. Six genes were differentially expressed in fAβ compared to BDTO. Both fAβ and BDTO preparations were confirmed via dot-blot analysis with conformation structural specific antibodies for oligomers (A11), fibrils (OC) and non-structural-specific antibodies for human Aβ (6E10) and tau oligomers (Tau22). Target genes were normalized to GAPDH and compared to vehicle expression by ΔΔCt. Bars show expression fold mean ± SEM. Red hash bar is ΔΔCt = 1Two. Two-Way ANOVA, followed by Sidak’s multiple-comparison post-hoc test, ***p<0.0001, **p<0.001, *p<0.05; n=6 wells/group. Data represented as mean ± SEM. See also Figures S5 and S6.
iMGLs gene profiles are responsive to neuronal environment(A) Schematic of iMGL co-culture with or without rat hippocampal neurons. (B) iMGLs co-cultured with neurons were collected, isolated by flow cytometry and transcriptomes evaluated via RNA-sequencing. (C) Heat map of iMGLs and iMGL-HC gene expression highlights uniquely enriched genes. (D) Differential gene expression analysis highlights 156 upregulated and 244 downregulated genes in iMGL-HCs. (E) Scatter plot of differentially expressed genes [> 2 Log2(FPKM+1)] highlight TRIM14, CABLES1, MMP2, SIGLEC 11 and 12, MITF, and SLC2A5 being enriched in iMGL-HCs, suggesting that iMGLs respond appropriately to a neuronal environment. Cells cultured alone are enriched for COMT, EGR2, EGR3, and FFAR2 suggesting a primed microglia phenotype. (F) GO and pathway terms from differential gene expression analysis of iMGLs cultured with hippocampal neurons. Genes upregulated in iMGL-HC are associated with 20 statistically significant pathway modules (green histogram) including positive cholesterol efflux, lipid transport, positive regulation of immune response, negative regulation of leukocyte differentiation and cell adhesion molecules. Cells cultured in absence of neurons had a complimentary gene profile with 20 statistically significant biological modules (blue histogram) including hallmark cholesterol homeostasis, hallmark TNFα signaling via NF-κB, leukocyte differentiation, and regulation of IL-1β secretion.
iMGLs respond to the neuronal environment in 3D brain organoid co-cultures (BORGS)iMGLs (5 × 105 cells) were added to media containing a single BORG for 7 days. (A) Representative bright-field image of iMGLs detected in and near BORG after 3 days. iMGLs were found in and attached to the BORG-media interface (arrows), but not free floating in the media, suggesting complete chemotaxis of iMGLs. (B) Representative image of iMGLs in outer and inner radius of BORG. (C) Embedded iMGLs exhibit macrophage-like morphology (white arrow) and extend processes (arrow) signifying ECM remodeling and surveillance respectively. Simultaneous assessment of embedded iMGL morphology in uninjured (D–F) and injured (G–I) BORGs. (D) Immunohistochemical analysis of BORGs reveals iMGLs begin tiling evenly throughout the BORG and project ramified processes for surveillance of the environment. BORGs are representative of developing brains in vitro and contain neurons (β3-tubulin, blue) and astrocytes (GFAP, red), which self-organize into a cortical-like distribution, but lack microglia. iMGLs (IBA1, green). (E–F) Representative immunofluorescent images of iMGLs with extended processes within the 3D CNS environment at higher magnification. (G–I) Representative images of iMGL morphology observed in injured BORG. (H–I) Round-bodied iMGLs reminiscent of amoeboid microglia are distributed in injured BORGs and closely resemble activated microglia, demonstrating that iMGLs respond appropriately to neuronal injury. Scale Bar (A–C) =50 μm in A-C, (D,G)= 200 μm (E–H)= 80 μm and (F,I) =15 μm.
iMGLs transplanted into the brains of either wild-type or AD transplant competent mice are like brain microgliaWithin the brains of xenotransplantation compatible mice, transplanted iMGLs are ramified and interact with the neuronal environment. (A–L) After two months in vivo, iMGLs transplanted into mice display long-term viability with highly arborized processes resembling endogenous microglia found in the brain. (A) Transplanted iMGLs, labeled with P2ry12 (green; HPA HPA014518, Sigma) and human nuclei (ku80, red), exhibit long-term viability in mice. (B–D) At higher magnification, P2ry12 is highly expressed in iMGL arborized processes, both suggestive of homeostatic microglia surveying the brain environment. (E–H) Ramified iMGLs also express microglia-enriched Tmem119 recognized by a human-specific Tmem119 antibody (green; ab185333, Abcam, identified and validated in [Bennet et al, PNAS 2016], and human cytoplasm maker SC121 (hCyto, red). (I–L) At higher magnification, representative iMGLs express P2ry12 (green), hCyto (red), and Iba1 (blue; ab5076, Abcam). (M–P) Human iMGLs (hCyto,red) transplanted into AD-immune-deficient mice (Marsh et al, PNAS 2016) interact with and phagocytose amyloid plaques (white). (I–J) Transplanted iMGLs extend projections and migrate to plaques. iMGLs fully encompass amyloid plaques (O) and begin to phagocytose amyloid (P). Scale bars; (A,E,N) = 30 μm, (B–D, F–H, I–L, O,P) = 10 μm, (M) = 300 μm. n=3 animals per study. See also Figure S7.
1–20 of 88
Next →
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Advances in hiPSC-Derived Brain Organoids as a Model to Study Neuroinflammation in Alzheimer's Disease. | Maciel EMA et al. | — | 2026 | → |
| Astrocytes and Microglia in Alzheimer's Disease: Friends, Foes, or Both? | Sharma A et al. | — | 2026 | → |
| Characterising processing conditions that artifactually bias human brain tissue transcriptomes. | Yaqubi M et al. | — | 2026 | → |
| Comparative lipidomics of iPSC-derived microglia protocols reveal lipid droplet and immune differences mediated by media composition. | Toda Robert A et al. | — | 2026 | → |
| CRISPR screens in iPSC-derived neurons reveal principles of tau proteostasis. | Samelson AJ et al. | — | 2026 | → |
| Dissecting microglial contributions to neurodegenerative disease pathophysiology using human pluripotent stem cells. | Kim D et al. | — | 2026 | → |
| Distinct transcriptional and epigenomic programs define Hofbauer cells in term placenta. | Baráth BR et al. | — | 2026 | → |
| Engineering a Perfusion Bioreactor System for hiPSC-Derived Progenitor Co-Culture Capturing Microglial Features in CNS Development. | Gomes CM et al. | — | 2026 | → |
| Exploring retinal microglia: development, degeneration, and iPSC-derived model systems. | Gao ML et al. | — | 2026 | → |
| From mechanisms to therapeutics: The expanding role of cell-based strategies in Alzheimer's disease. | Sun X et al. | — | 2026 | → |
| Functional genomic profiling of schizophrenia-associated genes reveals key microglial regulators. | Horng JE et al. | — | 2026 | → |
| Generating and characterizing human telencephalic brain organoids from stem cell-derived single neural rosettes. | Ullah HMA et al. | — | 2026 | → |
| Generation and characterization of iPSC-derived microglia for in vitro modeling of stimuli-specific neuroimmune responses. | Haskell AK et al. | — | 2026 | → |
| Glial dynamics in brain aging: Cellular heterogeneity and regional vulnerability. | Suk K | — | 2026 | → |
| Human cerebral organoids: Complex, versatile, and human-relevant models of neural development and brain diseases. | Coronel R et al. | — | 2026 | → |
| Immune response to adeno-associated viral vectors in a human iPSC-derived microglia chimeric mouse model. | Detrez JR et al. | — | 2026 | → |
| Immuno-Regulation of Brain Region-Specific Organoids Containing Isogenic Microglia-Like Cells. | Liu C et al. | — | 2026 | → |
| Inflammatory Mediators Both Directly and Indirectly Promote Microglial Proliferation. | Hammond BP et al. | — | 2026 | → |
| iPSC-derived microglia: Decoding roles and therapeutic opportunities in neurodegenerative diseases. | Shan D et al. | — | 2026 | → |
| Microglia-associated progression of multiple sclerosis: target identification and therapeutic engagement in human in vitro models. | Blenkle A et al. | — | 2026 | → |
| Microglia in systemic neuroimmune communication: functions beyond phagocytosis. | Di Pietro AA et al. | — | 2026 | → |
| Microglia replacement by ER-Hoxb8 conditionally immortalized macrophages provides insight into Aicardi-Goutières syndrome neuropathology. | Nemec KM et al. | — | 2026 | → |
| microRNA-132 attenuates inflammation in induced pluripotent stem cell-derived microglia from Alzheimer's disease patients. | Penning A et al. | — | 2026 | → |
| Modeling neurovascular dysfunction in Alzheimer's disease using an isogenic brain-chip model. | Shen AN et al. | — | 2026 | → |
| Modeling sporadic Alzheimer's disease using brain organoids: Emerging trends and translational opportunities. | Hossain MK et al. | — | 2026 | → |
| Neuroinflammatory crosstalk between microglia and astrocytes increases viral replication in an iPSC-derived model of CNS HIV infection. | Gesualdi J et al. | — | 2026 | → |
| Reconstructing human corticogenesis: Insights from cerebral organoids into neurodevelopment and disease modeling. | Tenreiro MF et al. | — | 2026 | → |
| Stem Cell Therapy and Models for Autism Spectrum Disorder: Insights and Research. | Liu Y et al. | — | 2026 | → |
| Synaptic effects of interleukin-6 on human iPSC-derived dopaminergic neurons. | Huang Y et al. | — | 2026 | → |
| The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-clearing program in microglia. | Albertini G et al. | — | 2026 | → |
| A 3D human iPSC-derived multi-cell type neurosphere system to model cellular responses to chronic amyloidosis. | Wendt S et al. | — | 2025 | → |
| A Comprehensive Review on Utilizing Human Brain Organoids to Study Neuroinflammation in Neurological Disorders. | Rubio AD et al. | — | 2025 | → |
| Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference. | Kloske CM et al. | — | 2025 | → |
| A feedback-driven brain organoid platform enables automated maintenance and high-resolution neural activity monitoring. | Voitiuk K et al. | — | 2025 | → |
| A neuroimmune cerebral assembloid model to study the pathophysiology of familial Alzheimer's disease. | Becerra-Calixto A et al. | — | 2025 | → |
| [Application of neural organoids containing microglia to neurodegenerative disease research]. | Harada K et al. | — | 2025 | → |
| APPswe mutation causes functional deficits in endothelial cells generated by transient ETV2 overexpression in human iPSCs. | Wu YC et al. | — | 2025 | → |
| "Armed <i>in-vitro</i> retina"-generating microglial retinal organoids, where are we now? | Liu Y et al. | — | 2025 | → |
| A scoping review of stem cell models of leukodystrophies: advances in understanding pathophysiological mechanisms. | Chapleau A et al. | — | 2025 | → |
| Assessing <i>in-vitro</i> models for microglial development and fetal programming: a critical review. | Schepanski S et al. | — | 2025 | → |
| Astrocyte induction of disease-associated microglia is suppressed by acute exposure to fAD neurons in human iPSC triple cultures. | Lish AM et al. | — | 2025 | → |
| A versatile mouse model to advance human microglia transplantation research in neurodegenerative diseases. | Serneels L et al. | — | 2025 | → |
| BRAFV600E induces key features of LCH in iPSCs with cell type-specific phenotypes and drug responses. | Abagnale G et al. | — | 2025 | → |
| Brain organoids: building higher-order complexity and neural circuitry models. | Maisumu G et al. | — | 2025 | → |
| Brain organoid technology in melanoma metastasis to the brain. | Rabinowitz G et al. | — | 2025 | → |
| Brain-wide microglia replacement using a nonconditioning strategy ameliorates pathology in mouse models of neurological disorders. | Chen D et al. | — | 2025 | → |
| Cell autonomous microglia defects in a stem cell model of frontotemporal dementia tau. | Iyer AK et al. | — | 2025 | → |
| Cellf-deception: human microglia clone 3 (HMC3) cells exhibit more astrocyte-like than microglia-like gene expression. | Rahm KK et al. | — | 2025 | → |
| Chimeric human organoid and mouse brain slice co-cultures to study microglial function. | Panagiotakopoulou V et al. | — | 2025 | → |
| Chronic alcohol consumption induces phenotypic and functional alterations consistent with a hyper-inflammatory state in peripheral blood mononuclear cell-derived microglia in a rhesus macaque model. | Hemati H et al. | — | 2025 | → |
| CLU alleviates Alzheimer's disease-relevant processes by modulating astrocyte reactivity and microglia-dependent synaptic density. | Lish AM et al. | — | 2025 | → |
| Contributions of Genetic Variation in Astrocytes to Cell and Molecular Mechanisms of Risk and Resilience to Late-Onset Alzheimer's Disease. | Lee H et al. | — | 2025 | → |
| Current Development of iPSC-Based Modeling in Neurodegenerative Diseases. | Guo X et al. | — | 2025 | → |
| Current Position and Future Direction of Inflammation in Neuropsychiatric Disorders: A Review. | Upthegrove R et al. | — | 2025 | → |
| Cytokine-induced reprogramming of human macrophages toward Alzheimer's disease-relevant molecular and cellular phenotypes in vitro. | Podleśny-Drabiniok A et al. | — | 2025 | → |
| Decoding microglial functions in Alzheimer's disease: insights from human models. | Rao C et al. | — | 2025 | → |
| Development and characterization of in vitro inducible immortalization of a murine microglia cell line for high throughput studies. | Yeh H et al. | — | 2025 | → |
| Differential Responses of Human iPSC-Derived Microglia to Stimulation with Diverse Inflammogens. | Wolfbeisz C et al. | — | 2025 | → |
| Dual PDE4/10A inhibition restores CREB1 function and enhances neuronal resilience in models of alzheimer's disease. | Rong X et al. | — | 2025 | → |
| Dysregulation of huntingtin interacting protein networks in human juvenile Huntington's disease brain. | Podvin S et al. | — | 2025 | → |
| Emerging brain organoids: 3D models to decipher, identify and revolutionize brain. | Zhao Y et al. | — | 2025 | → |
| Emerging Insights into Brain Inflammation: Stem-Cell-Based Approaches for Regenerative Medicine. | Karam M et al. | — | 2025 | → |
| Engineered 3D immuno-glial-neurovascular human miBrain model. | Stanton AE et al. | — | 2025 | → |
| Engineering brain organoids and organ-on-chip systems for modeling neurodevelopmental and neurodegenerative pathophysiology. | Banerjee S et al. | — | 2025 | → |
| Establishing Neural Organoid Cultures for Investigating the Effects of Microgravity in Low-Earth Orbit (LEO). | Pirjanian NA et al. | — | 2025 | → |
| Ethanol-induced changes in neurotrophic and immune genes are regulated by receptor-type protein tyrosine phosphatase β/ζ (RPTPβ/ζ) and microglial-neuronal interactions. | Penedo MA et al. | — | 2025 | → |
| Expanding the neuroimmune research toolkit with in vivo brain organoid technologies. | Tian A et al. | — | 2025 | → |
| Exploring human brain development and disease using assembloids. | Wu SR et al. | — | 2025 | → |
| Extracellular microRNAs modulate human microglial function through TLR8. | Weidling H et al. | — | 2025 | → |
| Forced polarisation of microglia by IL-13 is modified by inflammatory and microenvironmental context. | Aiyegbusi ED et al. | — | 2025 | → |
| GD2-CAR-Engineered Microglia Exhibit Antitumor Effects in Organoids and Animal Models of Retinoblastoma. | Xu J et al. | — | 2025 | → |
| Generation, interrogation, and future applications of microglia-containing brain organoids. | Di Stefano J et al. | — | 2025 | → |
| Generation of Neural Organoids and Their Application in Disease Modeling and Regenerative Medicine. | Huang R et al. | — | 2025 | → |
| Genetically Engineered Mouse Models for Alzheimer Disease and Frontotemporal Dementia: New Insights from Single-Cell and Spatial Transcriptomics. | Chiu Y et al. | — | 2025 | → |
| GRAMD1B is a regulator of lipid homeostasis, autophagic flux and phosphorylated tau. | Acosta Ingram D et al. | — | 2025 | → |
| Harnessing human iPSC-microglia for CNS-wide delivery of disease-modifying proteins. | Chadarevian JP et al. | — | 2025 | → |
| HDAC inhibitors engage MITF and the disease-associated microglia signature to enhance amyloid β uptake. | Haage V et al. | — | 2025 | → |
| Human brain organoids: an innovative model for neurological disorder research and therapy. | Li H et al. | — | 2025 | → |
| Human iPSC-Derived Microglia Integrate Into Cerebral Organoids and Assume an In Vivo-Like Phenotype. | Wogram E et al. | — | 2025 | → |
| Human Microglia-Like Cells Differentiated from Monocytes with GM-CSF and IL-34 Show Phagocytosis of α-Synuclein Aggregates and C/EBPβ-Dependent Proinflammatory Activation. | Llaves-López A et al. | — | 2025 | → |
| Human Microglia Models for NeuroHIV. | Sarkar P et al. | — | 2025 | → |
| Human microglia reduce alpha-synuclein aggregation and are neuroprotective in adult mouse brain. | Albert K et al. | — | 2025 | → |
| Induced pluripotent stem cell-derived macrophages as a platform for modelling human disease. | Tiwari SK et al. | — | 2025 | → |
| Inflammation-induced lysosomal dysfunction in human iPSC-derived microglia is exacerbated by APOE 4/4 genotype. | Hellén M et al. | — | 2025 | → |
| Inflammatory responses revealed through HIV infection of microglia-containing cerebral organoids. | Narasipura SD et al. | — | 2025 | → |
| Inhaled xenon modulates microglia and ameliorates disease in mouse models of amyloidosis and tauopathy. | Brandao W et al. | — | 2025 | → |
| Inhibition of Acyl-CoenzymeA: Cholesterol Acyltransferase 1 promotes shedding of soluble triggering receptor on myeloid cells 2 (TREM2) and low-density lipoprotein receptor 1 (LRP1)-dependent phagocytosis of amyloid beta protein in microglia. | Hovde MJ et al. | — | 2025 | → |
| Integrating Macrophages into Human-Engineered Cardiac Tissue. | Zhao YP et al. | — | 2025 | → |
| Integration and functionality of human iPSC-derived microglia in a chimeric mouse retinal model. | Tang C et al. | — | 2025 | → |
| Iterative transcription factor screening enables rapid generation of microglia-like cells from human iPSC. | Liu S et al. | — | 2025 | → |
| Lessons from ex vivo and in vitro models in microglia research. | Cserép C et al. | — | 2025 | → |
| Long-Term Engraftment of Cryopreserved Human Neurons for In Vivo Disease Modeling in Neurodegenerative Disease. | Marmion DJ et al. | — | 2025 | → |
| <i>SAMHD1</i> knockout hiPSC model enables high lentiviral transduction efficiency in myeloid cell types. | Li H et al. | — | 2025 | → |
| Machine learning-assisted design of immunomodulatory lipid nanoparticles for delivery of mRNA to repolarize hyperactivated microglia. | Rafiei M et al. | — | 2025 | → |
| Microglia determine an immune-challenged environment and facilitate ibuprofen action in human retinal organoids. | Schmied V et al. | — | 2025 | → |
| Microglia from patients with multiple sclerosis display a cell-autonomous immune activation state. | Hyvärinen T et al. | — | 2025 | → |
| Microglia heterogeneity, modeling and cell-state annotation in development and neurodegeneration. | Fumagalli L et al. | — | 2025 | → |
| Microglia in ALS: Insights into Mechanisms and Therapeutic Potential. | Bond S et al. | — | 2025 | → |
| Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States. | Kuhn MK et al. | — | 2025 | → |
| Microglia-like cells from patient monocytes demonstrate increased phagocytic activity in probable Alzheimer's disease. | Gonul CP et al. | — | 2025 | → |
| Microglial involvement in autism spectrum disorder: insights from human data and iPSC models. | Michels S et al. | — | 2025 | → |
| Microglial lipid phosphatase SHIP1 limits complement-mediated synaptic pruning in the healthy developing hippocampus. | Matera A et al. | — | 2025 | → |
| Microglial replacement in a Sandhoff disease mouse model reveals myeloid-derived β-hexosaminidase is necessary for neuronal health. | Tsourmas KI et al. | — | 2025 | → |
| Microglia regulate GABAergic neurogenesis in prenatal human brain through IGF1. | Yu D et al. | — | 2025 | → |
| Microglia transcriptional states and their functional significance: Context drives diversity. | Depp C et al. | — | 2025 | → |
| Modeling neurodegenerative diseases with brain organoids: from development to disease applications. | Larriba-González T et al. | — | 2025 | → |
| Modeling neuroinflammatory interactions between microglia and astrocytes in a human iPSC-based coculture platform. | Tujula I et al. | — | 2025 | → |
| Modelling human brain development and disease with organoids. | Birtele M et al. | — | 2025 | → |
| Neuroinflammation across the Spectrum of Neurodegenerative Diseases: Mechanisms and Therapeutic Frontiers. | Alemán-Villa KM et al. | — | 2025 | → |
| Neuroinflammation: targeting microglia for neuroprotection and repair after spinal cord injury. | Cavalcanti RR et al. | — | 2025 | → |
| Neuronal TDP-43 aggregation drives changes in microglial morphology prior to immunophenotype in amyotrophic lateral sclerosis. | Swanson MEV et al. | — | 2025 | → |
| Niche-specific therapeutic targeting of myeloid cells in the central nervous system. | Frosch M et al. | — | 2025 | → |
| Novel fully human high-affinity anti-TREM2 antibody shows efficacy in clinically relevant Alzheimer´s mouse model. | Kraller M et al. | — | 2025 | → |
| Perfluoroalkyl substance pollutants disrupt microglia function and trigger transcriptional and epigenomic changes. | Cheng Y et al. | — | 2025 | → |
| POU3F2 regulates canonical Wnt signalling via SOX13 and ADNP to expand the neural progenitor population. | Benoit CR et al. | — | 2025 | → |
| Prenatal opioid exposure and maternal HCV infection impair microglia development and function: A patient-specific in vitro model. | True HE et al. | — | 2025 | → |
| Pro-resolving lipid mediator reduces amyloid-β42-induced gene expression in human monocyte-derived microglia. | Wang Y et al. | — | 2025 | → |
| Protocol for generating a human iPSC-derived tri-culture model to study interactions between neurons, astrocytes, and microglia. | Lish AM et al. | — | 2025 | → |
| Protocol for generating and using human iPSC-derived microglia-containing air-liquid-interface cortical organoid cultures. | Cañizares Luna M et al. | — | 2025 | → |
| Protocol to assess engulfment and degradation of synaptosomes by murine microglia in vitro. | Matera A et al. | — | 2025 | → |
| Stem Cell-Based Approaches for Spinal Cord Injury: The Promise of iPSCs. | Zeng CW | — | 2025 | → |
| Stem cells therapy in neurodegenerative and neuroimmune diseases: Current status of treatments and future prospects. | Shi M et al. | — | 2025 | → |
| Sustaining Brain Youth by Neural Stem Cells: Physiological and Therapeutic Perspectives. | Santos M et al. | — | 2025 | → |
| Systematic analysis of cellular cross-talk reveals a role for SEMA6D-TREM2 regulating microglial function in Alzheimer's disease. | D'Oliveira Albanus R et al. | — | 2025 | → |
| Targeting formyl peptide receptor 1 reduces brain inflammation and neurodegeneration. | Li Y et al. | — | 2025 | → |
| TET2-mutant myeloid cells mitigate Alzheimer's disease progression via CNS infiltration and enhanced phagocytosis in mice. | Matatall KA et al. | — | 2025 | → |
| The complement cascade in Alzheimer's disease: modern implications of an ancient immune protagonist. | Papavergi MT et al. | — | 2025 | → |
| The current approaches to modeling the brain ischemia-reperfusion and inflammation: from animal models toward vascularized and neuroimmune cerebral organoids. | Tregub PP et al. | — | 2025 | → |
| The evolution of microglia replacement: A new paradigm for CNS disease therapy. | Rao Y et al. | — | 2025 | → |
| The P2Y13 receptor-mediated microglial morphological transformation through the p38MAPK signaling pathway contributes to central sensitization in a murine model of chronic migraine. | Yang Y et al. | — | 2025 | → |
| The pathophysiology of mixed Alzheimer's disease and vascular dementia. | Sarhan M et al. | — | 2025 | → |
| The potential of brain organoids in addressing the heterogeneity of synucleinopathies. | Diao XJ et al. | — | 2025 | → |
| The protective PLCγ2-P522R variant mitigates Alzheimer's disease-associated pathologies by enhancing beneficial microglial functions. | Takalo M et al. | — | 2025 | → |
| The Rise of Pluripotent Stem Cell-Derived Glia Models of Neuroinflammation. | Kala S et al. | — | 2025 | → |
| The transcription factor MEF2C restrains microglial overactivation by inhibiting kinase CDK2. | Hu X et al. | — | 2025 | → |
| Towards a quality control framework for cerebral cortical organoids. | Castiglione H et al. | — | 2025 | → |
| Transcriptional and epigenetic targets of MEF2C in human microglia contribute to cellular functions related to autism risk and age-related disease. | Nguyen C et al. | — | 2025 | → |
| Transcription Factor-Based Differentiation of Pluripotent Stem Cells: Overcoming the Traps of Random Neuronal Fate. | McDaid G et al. | — | 2025 | → |
| Two- and Three-Dimensional In Vitro Models of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Applications. | Solana-Manrique C et al. | — | 2025 | → |
| Uncovering plaque-glia niches in human Alzheimer's disease brains using spatial transcriptomics. | Avey DR et al. | — | 2025 | → |
| Understanding monocyte-driven neuroinflammation in Alzheimer's disease using human cortical organoid microphysiological systems. | Tian C et al. | — | 2025 | → |
| Unraveling APOE4: The dual role in CNS and peripheral inflammation in Alzheimer's disease. | Li X et al. | — | 2025 | → |
| Uptake of alpha-synuclein preformed fibrils is suppressed by inflammation and induces an aberrant phenotype in human microglia. | Niskanen J et al. | — | 2025 | → |
| Vascular models of Alzheimer's disease: An overview of recent in vitro models of the blood-brain barrier. | Takeuchi LE et al. | — | 2025 | → |
| Visualize neuronal membrane cholesterol with split-fluorescent protein tagged YDQA sensor. | Xu Y et al. | — | 2025 | → |
| Adaptation of Human iPSC-Derived Macrophages Toward an Alveolar Macrophage-Like Phenotype Post-Intra-Pulmonary Transfer into Murine Models. | Hetzel M et al. | — | 2024 | → |
| Adult microglial TGFβ1 is required for microglia homeostasis via an autocrine mechanism to maintain cognitive function in mice. | Bedolla A et al. | — | 2024 | → |
| Advanced patient-specific microglia cell models for pre-clinical studies in Alzheimer's disease. | Cuní-López C et al. | — | 2024 | → |
| Advances in physiological and clinical relevance of hiPSC-derived brain models for precision medicine pipelines. | Imani Farahani N et al. | — | 2024 | → |
| Advancing Alzheimer's Disease Modelling by Developing a Refined Biomimetic Brain Microenvironment for Facilitating High-Throughput Screening of Pharmacological Treatment Strategies. | Mohd Murshid N et al. | — | 2024 | → |
| Aging phenotype in AD brain organoids: Track to success and challenges. | Hossain MK et al. | — | 2024 | → |
| A glia-enriched stem cell 3D model of the human brain mimics the glial-immune neurodegenerative phenotypes of multiple sclerosis. | Fagiani F et al. | — | 2024 | → |
| Altered metabolism and DAM-signatures in female brains and microglia with aging. | Cleland NRW et al. | — | 2024 | → |
| An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders. | Dorion MF et al. | — | 2024 | → |
| An integrated toolkit for human microglia functional genomics. | Haq I et al. | — | 2024 | → |
| A Novel Approach to Increase Glial Cell Populations in Brain Microphysiological Systems. | Morales Pantoja IE et al. | — | 2024 | → |
| An Overview of Multiple Sclerosis In Vitro Models. | Czpakowska J et al. | — | 2024 | → |
| Apolipoprotein E aggregation in microglia initiates Alzheimer's disease pathology by seeding β-amyloidosis. | Kaji S et al. | — | 2024 | → |
| Application Prospect of Induced Pluripotent Stem Cells in Organoids and Cell Therapy. | Zhang T et al. | — | 2024 | → |
| Assembloid models of cell-cell interaction to study tissue and disease biology. | Onesto MM et al. | — | 2024 | → |
| ATM-deficiency-induced microglial activation promotes neurodegeneration in ataxia-telangiectasia. | Lai J et al. | — | 2024 | → |
| Brain organoid methodologies to explore mechanisms of disease in progressive multiple sclerosis. | Simões-Abade MBC et al. | — | 2024 | → |
| Brain organoid models for studying the function of iPSC-derived microglia in neurodegeneration and brain tumours. | Sabogal-Guaqueta AM et al. | — | 2024 | → |
| Brain organoids: A new tool for modelling of neurodevelopmental disorders. | Aili Y et al. | — | 2024 | → |
| Brain organoids engineered to give rise to glia and neural networks after 90 days in culture exhibit human-specific proteoforms. | Wenzel TJ et al. | — | 2024 | → |
| Challenges and Future Perspectives in Modeling Neurodegenerative Diseases Using Organ-on-a-Chip Technology. | Pramotton FM et al. | — | 2024 | → |
| Comparison of Extracellular Vesicles from Induced Pluripotent Stem Cell-Derived Brain Cells. | Xavier G et al. | — | 2024 | → |
| Design of neural organoids engineered by mechanical forces. | Suong DNA et al. | — | 2024 | → |
| Emerging Human Pluripotent Stem Cell-Based Human-Animal Brain Chimeras for Advancing Disease Modeling and Cell Therapy for Neurological Disorders. | Ji Y et al. | — | 2024 | → |
| Emerging Models to Study Human Microglia In vitro. | Jäntti H et al. | — | 2024 | → |
| ER and SOCE Ca<sup>2+</sup> signals are not required for directed cell migration in human iPSC-derived microglia. | Granzotto A et al. | — | 2024 | → |
| Experimental Cell Models for Investigating Neurodegenerative Diseases. | Evangelisti C et al. | — | 2024 | → |
| Expression of ALS-PFN1 impairs vesicular degradation in iPSC-derived microglia. | Funes S et al. | — | 2024 | → |
| Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. | Langlois J et al. | — | 2024 | → |
| Forward programming human pluripotent stem cells into microglia. | Csatári J et al. | — | 2024 | → |
| Glia in tissue engineering: From biomaterial tools to transplantation. | Dill-Macky AS et al. | — | 2024 | → |
| Harnessing the potential of human induced pluripotent stem cells, functional assays and machine learning for neurodevelopmental disorders. | Yang Z et al. | — | 2024 | → |
| Histone acetylation in an Alzheimer's disease cell model promotes homeostatic amyloid-reducing pathways. | Xu DC et al. | — | 2024 | → |
| Human brain organoids containing microglia that have arisen innately adapt to a β-amyloid challenge better than those in which microglia are integrated by co-culture. | Wenzel TJ et al. | — | 2024 | → |
| Human-induced pluripotent stem cell-derived microglia integrate into mouse retina and recapitulate features of endogenous microglia. | Ma W et al. | — | 2024 | → |
| Human iPSC-derived microglia sense and dampen hyperexcitability of cortical neurons carrying the epilepsy-associated <i>SCN2A</i>-L1342P mutation. | Que Z et al. | — | 2024 | → |
| Humanized brain organoids-on-chip integrated with sensors for screening neuronal activity and neurotoxicity. | Saglam-Metiner P et al. | — | 2024 | → |
| Human microglia-derived proinflammatory cytokines facilitate human retinal ganglion cell development and regeneration. | Subramani M et al. | — | 2024 | → |
| Human-mouse chimeric brain models constructed from iPSC-derived brain cells: Applications and challenges. | Zhao Y et al. | — | 2024 | → |
| Human pluripotent stem cell (hPSC)-derived microglia for the study of brain disorders. A comprehensive review of existing protocols. | Teo F et al. | — | 2024 | → |
| Human pluripotent stem cells as a translational toolkit in psychedelic research <i>in vitro</i>. | Salerno JA et al. | — | 2024 | → |
| Human stem cell transplantation models of Alzheimer's disease. | Ifediora N et al. | — | 2024 | → |
| Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB. | Clarke BE et al. | — | 2024 | → |
| Immunology of Retinitis Pigmentosa and Gene Therapy-Associated Uveitis. | Yang P et al. | — | 2024 | → |
| Induced Pluripotent Stem Cells and Organoids in Advancing Neuropathology Research and Therapies. | Pazzin DB et al. | — | 2024 | → |
| Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling. | Beghini DG et al. | — | 2024 | → |
| Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. | Cerneckis J et al. | — | 2024 | → |
| Integration of iPSC-Derived Microglia into Brain Organoids for Neurological Research. | Mrza MA et al. | — | 2024 | → |
| Investigating the neurobiology of maternal opioid use disorder and prenatal opioid exposure using brain organoid technology. | Dwivedi I et al. | — | 2024 | → |
| iPSC-derived PSEN2 (N141I) astrocytes and microglia exhibit a primed inflammatory phenotype. | Sullivan MA et al. | — | 2024 | → |
| Limitations of human brain organoids to study neurodegenerative diseases: a manual to survive. | Urrestizala-Arenaza N et al. | — | 2024 | → |
| Loss of Function in the Neurodevelopmental Disease and Schizophrenia-Associated Gene CYFIP1 in Human Microglia-like Cells Supports a Functional Role in Synaptic Engulfment. | Sheridan SD et al. | — | 2024 | → |
| Macrophages derived from human induced pluripotent stem cells (iPSCs) serve as a high-fidelity cellular model for investigating HIV-1, dengue, and influenza viruses. | Yang Q et al. | — | 2024 | → |
| Maternal SARS-CoV-2 impacts fetal placental macrophage programs and placenta-derived microglial models of neurodevelopment. | Shook LL et al. | — | 2024 | → |
| Microglia Gravitate toward Amyloid Plaques Surrounded by Externalized Phosphatidylserine via TREM2. | Park JC et al. | — | 2024 | → |
| Microglia in Health and Diseases: Integrative Hubs of the Central Nervous System (CNS). | Sierra A et al. | — | 2024 | → |
| Microglial APOE3 Christchurch protects neurons from Tau pathology in a human iPSC-based model of Alzheimer's disease. | Sun GG et al. | — | 2024 | → |
| Microglial over-pruning of synapses during development in autism-associated SCN2A-deficient mice and human cerebral organoids. | Wu J et al. | — | 2024 | → |
| Microglia-mediated neuron death requires TNF and is exacerbated by mutant Huntingtin. | Young AP et al. | — | 2024 | → |
| Microglia replacement by ER-Hoxb8 conditionally immortalized macrophages provides insight into Aicardi-Goutières Syndrome neuropathology | Nemec KM et al. | — | 2024 | — |
| Modeling Alzheimer's disease using human cell derived brain organoids and 3D models. | Fernandes S et al. | — | 2024 | → |
| Modeling neuropathic pain in a dish. | Zebochin I et al. | — | 2024 | → |
| Modeling tuberous sclerosis complex with human induced pluripotent stem cells. | Niu W et al. | — | 2024 | → |
| Myeloid cell-specific loss of NPC1 in mice recapitulates microgliosis and neurodegeneration in patients with Niemann-Pick type C disease. | Dinkel L et al. | — | 2024 | → |
| Neuroimmune mechanisms in autism etiology - untangling a complex problem using human cellular models. | Vacharasin JM et al. | — | 2024 | → |
| Neurotoxic Microglial Activation via IFNγ-Induced Nrf2 Reduction Exacerbating Alzheimer's Disease. | Kang YJ et al. | — | 2024 | → |
| New developments in pre-clinical models of ALS to guide translation. | De Cock L et al. | — | 2024 | → |
| Novel human iPSC models of neuroinflammation in neurodegenerative disease and regenerative medicine. | Summers RA et al. | — | 2024 | → |
| Particulate matter from car exhaust alters function of human iPSC-derived microglia. | Jäntti H et al. | — | 2024 | → |
| Peripheral expression of brain-penetrant progranulin rescues pathologies in mouse models of frontotemporal lobar degeneration. | Reich M et al. | — | 2024 | → |
| Pharmacological inhibition of receptor protein tyrosine phosphatase β/ζ decreases Aβ plaques and neuroinflammation in the hippocampus of APP/PS1 mice. | Fontán-Baselga T et al. | — | 2024 | → |
| Polygenic risk for alcohol use disorder affects cellular responses to ethanol exposure in a human microglial cell model. | Li X et al. | — | 2024 | → |
| Promoting Alzheimer's disease research and therapy with stem cell technology. | Cao Z et al. | — | 2024 | → |
| Ready-to-use iPSC-derived microglia progenitors for the treatment of CNS disease in mouse models of neuropathic mucopolysaccharidoses. | Douvaras P et al. | — | 2024 | → |
| Recapitulation and investigation of human brain development with neural organoids. | Tamada A et al. | — | 2024 | → |
| Recent advances and current challenges of new approach methodologies in developmental and adult neurotoxicity testing. | Serafini MM et al. | — | 2024 | → |
| Regulation of human microglial gene expression and function via RNAase-H active antisense oligonucleotides in vivo in Alzheimer's disease. | Vandermeulen L et al. | — | 2024 | → |
| Remyelination in the Central Nervous System. | Franklin RJM et al. | — | 2024 | → |
| Retinal Organoid Microenvironment Enhanced Bioactivities of Microglia-Like Cells Derived From HiPSCs. | Gao ML et al. | — | 2024 | → |
| Rigor and reproducibility in human brain organoid research: Where we are and where we need to go. | Sandoval SO et al. | — | 2024 | → |
| Stem cell modeling of nervous system tumors. | Furnari FB et al. | — | 2024 | → |
| Stem cell therapy in Alzheimer's disease: current status and perspectives. | Ou CM et al. | — | 2024 | → |
| Sustained type I interferon signaling after human immunodeficiency virus type 1 infection of human iPSC derived microglia and cerebral organoids. | Boreland AJ et al. | — | 2024 | → |
| The complement system in neurodegenerative diseases. | Nimmo J et al. | — | 2024 | → |
| The involvement of α-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease. | Miao Y et al. | — | 2024 | → |
| Therapeutic potential of human microglia transplantation in a chimeric model of CSF1R-related leukoencephalopathy. | Chadarevian JP et al. | — | 2024 | → |
| Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases. | Wißfeld J et al. | — | 2024 | → |
| The Role of Human Pluripotent Stem Cells in Amyotrophic Lateral Sclerosis: From Biological Mechanism to Practical Implications. | Ceccarelli L et al. | — | 2024 | → |
| Transcriptional characterization of iPSC-derived microglia as a model for therapeutic development in neurodegeneration. | Ramaswami G et al. | — | 2024 | → |
| Transcriptomic and proteomic profiling of bi-partite and tri-partite murine iPSC-derived neurospheroids under steady-state and inflammatory condition. | Di Stefano J et al. | — | 2024 | → |
| Updates on mouse models of Alzheimer's disease. | Zhong MZ et al. | — | 2024 | → |
| Varicella-zoster virus recapitulates its immune evasive behaviour in matured hiPSC-derived neurospheroids. | Govaerts J et al. | — | 2024 | → |
| Vascularized Brain Assembloids With Enhanced Cellular Complexity Provide Insights Into the Cellular Deficits of Tauopathy. | Sun X et al. | — | 2024 | → |
| A beginner's guide on the use of brain organoids for neuroscientists: a systematic review. | Mulder LA et al. | — | 2023 | → |
| Advances and Applications of Brain Organoids. | Li Y et al. | — | 2023 | → |
| Advances in current <i>in vitro</i> models on neurodegenerative diseases. | Pereira I et al. | — | 2023 | → |
| Advancing cell therapy for neurodegenerative diseases. | Temple S | — | 2023 | → |
| Aging microglia. | Antignano I et al. | — | 2023 | → |
| Alteration of microglial metabolism and inflammatory profile contributes to neurotoxicity in a hiPSC-derived microglia model of frontotemporal dementia 3. | Haukedal H et al. | — | 2023 | → |
| Alzheimer's genes in microglia: a risk worth investigating. | Sudwarts A et al. | — | 2023 | → |
| Analysis of Aβ-induced neurotoxicity and microglial responses in simple two- and three-dimensional human iPSC-derived cortical culture systems. | Takata M et al. | — | 2023 | → |
| An in vivo neuroimmune organoid model to study human microglia phenotypes. | Schafer ST et al. | — | 2023 | → |
| An overall view of the most common experimental models for multiple sclerosis. | Dedoni S et al. | — | 2023 | → |
| APOE and immunity: Research highlights. | Kloske CM et al. | — | 2023 | → |
| Application of Human Brain Organoids-Opportunities and Challenges in Modeling Human Brain Development and Neurodevelopmental Diseases. | Kim SH et al. | — | 2023 | → |
| Applications of Induced Pluripotent Stem Cell-Derived Glia in Brain Disease Research and Treatment. | Yang Z et al. | — | 2023 | → |
| A review of protocols for brain organoids and applications for disease modeling. | Mayhew CN et al. | — | 2023 | → |
| A toolbox for studying the transcriptional diversity and functions of human microglia in vitro. | — | — | 2023 | → |
| A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models. | van Lengerich B et al. | — | 2023 | → |
| Autism Spectrum Disorder: A Neuro-Immunometabolic Hypothesis of the Developmental Origins. | Frasch MG et al. | — | 2023 | → |
| Bioelectronic medicine potentiates endogenous NSCs for neurodegenerative diseases. | Yu M et al. | — | 2023 | → |
| Brain organoids for hypoxic-ischemic studies: from bench to bedside. | Gaston-Breton R et al. | — | 2023 | → |
| Bridging Retinal and Cerebral Neurodegeneration: A Focus on Crosslinks between Alzheimer-Perusini's Disease and Retinal Dystrophies. | Donato L et al. | — | 2023 | → |
| Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease. | Liu CC et al. | — | 2023 | → |
| Cell-type-specific regulation of APOE and CLU levels in human neurons by the Alzheimer's disease risk gene SORL1. | Lee H et al. | — | 2023 | → |
| Cellular senescence and neurodegeneration. | Holloway K et al. | — | 2023 | → |
| Collagen for neural tissue engineering: Materials, strategies, and challenges. | Huang WH et al. | — | 2023 | → |
| Complexity of Sex Differences and Their Impact on Alzheimer's Disease. | Kadlecova M et al. | — | 2023 | → |
| Comprehensive Bibliometric Analysis of Stem Cell Research in Alzheimer's Disease from 2004 to 2022. | Wang R et al. | — | 2023 | → |
| Context matters: hPSC-derived microglia thrive in a humanized brain environment in vivo. | Cerneckis J et al. | — | 2023 | → |
| CRISPR generation of CSF1R-G795A human microglia for robust microglia replacement in a chimeric mouse model. | Chadarevian JP et al. | — | 2023 | → |
| Defects in lysosomal function and lipid metabolism in human microglia harboring a TREM2 loss of function mutation. | Filipello F et al. | — | 2023 | → |
| Development of a three-dimensional organoid model to explore early retinal phenotypes associated with Alzheimer's disease. | Lavekar SS et al. | — | 2023 | → |
| Development of brain organoid technology derived from iPSC for the neurodegenerative disease modelling: a glance through. | Jusop AS et al. | — | 2023 | → |
| Differentiation of neurosphere after transplantation into the damaged spinal cord. | Gramatiuk SM et al. | — | 2023 | → |
| Directed Differentiation of Human iPSCs into Microglia-Like Cells Using Defined Transcription Factors. | Chen SW et al. | — | 2023 | → |
| Divergent functional outcomes of NLRP3 blockade downstream of multi-inflammasome activation: therapeutic implications for ALS. | Clénet ML et al. | — | 2023 | → |
| Engineering an inhibitor-resistant human CSF1R variant for microglia replacement. | Chadarevian JP et al. | — | 2023 | → |
| Exposure of iPSC-derived human microglia to brain substrates enables the generation and manipulation of diverse transcriptional states in vitro. | Dolan MJ et al. | — | 2023 | → |
| FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity. | Wieder N et al. | — | 2023 | → |
| From neurodevelopment to neurodegeneration: utilizing human stem cell models to gain insight into Down syndrome. | Watson LA et al. | — | 2023 | → |
| Functional characterization of Alzheimer's disease genetic variants in microglia. | Yang X et al. | — | 2023 | → |
| Give Them Vasculature and Immune Cells: How to Fill the Gap of Organoids. | Yip S et al. | — | 2023 | → |
| Herpesvirus Infections in the Human Brain: A Neural Cell Model of the Complement System Derived from Induced Pluripotent Stem Cells. | Marques ETA et al. | — | 2023 | → |
| HIV-1 infection of genetically engineered iPSC-derived central nervous system-engrafted microglia in a humanized mouse model. | Min AK et al. | — | 2023 | → |
| Human brain microphysiological systems in the study of neuroinfectious disorders. | Barreras P et al. | — | 2023 | → |
| Human brain organoid model of maternal immune activation identifies radial glia cells as selectively vulnerable. | Sarieva K et al. | — | 2023 | → |
| Human cortical spheroids with a high diversity of innately developing brain cell types. | De Kleijn KMA et al. | — | 2023 | → |
| Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons and Glia for the Elucidation of Pathogenic Mechanisms in Alzheimer's Disease. | Young JE et al. | — | 2023 | → |
| Human iPSC-derived glia models for the study of neuroinflammation. | Stöberl N et al. | — | 2023 | → |
| Human iPSC-derived microglia carrying the LRRK2-G2019S mutation show a Parkinson's disease related transcriptional profile and function. | Ohtonen S et al. | — | 2023 | → |
| Human isogenic cells of the neurovascular unit exert transcriptomic cell type-specific effects on a blood-brain barrier in vitro model of late-onset Alzheimer disease. | Haferkamp U et al. | — | 2023 | → |
| Human microglial models to study host-virus interactions. | McMillan RE et al. | — | 2023 | → |
| Human myeloid progenitor glucocorticoid receptor activation causes genomic instability, type 1 IFN- response pathway activation and senescence in differentiated microglia; an early life stress model. | Wei J et al. | — | 2023 | → |
| Incorporating microglia-like cells in human induced pluripotent stem cell-derived retinal organoids. | Chichagova V et al. | — | 2023 | → |
| Infiltrating CD8<sup>+</sup> T cells exacerbate Alzheimer's disease pathology in a 3D human neuroimmune axis model. | Jorfi M et al. | — | 2023 | → |
| Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases. | Nainu F et al. | — | 2023 | → |
| Innate immune activation and aberrant function in the R6/2 mouse model and Huntington's disease iPSC-derived microglia. | Gasser J et al. | — | 2023 | → |
| INPP5D regulates inflammasome activation in human microglia. | Chou V et al. | — | 2023 | → |
| Insights into Gene Regulation under Temozolomide-Promoted Cellular Dormancy and Its Connection to Stemness in Human Glioblastoma. | Kubelt C et al. | — | 2023 | → |
| Investigating nanoplastics toxicity using advanced stem cell-based intestinal and lung <i>in vitro</i> models. | Busch M et al. | — | 2023 | → |
| iPS-cell-derived microglia promote brain organoid maturation via cholesterol transfer. | Park DS et al. | — | 2023 | → |
| Leveraging iPSC technology to assess neuro-immune interactions in neurological and psychiatric disorders. | Michalski C et al. | — | 2023 | → |
| Mesenchymal stem cell-derived neural progenitors attenuate proinflammatory microglial activation via paracrine mechanisms. | Harris VK et al. | — | 2023 | → |
| Microglia-containing human brain organoids for the study of brain development and pathology. | Zhang W et al. | — | 2023 | → |
| Microglia innate immune response contributes to the antiviral defense and blood-CSF barrier function in human choroid plexus organoids during HSV-1 infection. | Qiao H et al. | — | 2023 | → |
| Microglial Activation: Key Players in Sepsis-Associated Encephalopathy. | Hu J et al. | — | 2023 | → |
| Microglial contribution to the pathology of neurodevelopmental disorders in humans. | Matuleviciute R et al. | — | 2023 | → |
| Midbrain organoids-development and applications in Parkinson's disease. | Toh HSY et al. | — | 2023 | → |
| Mitochondria dysregulation contributes to secondary neurodegeneration progression post-contusion injury in human 3D in vitro triculture brain tissue model. | Liaudanskaya V et al. | — | 2023 | → |
| Modeling brain macrophage biology and neurodegenerative diseases using human iPSC-derived neuroimmune organoids. | Cerneckis J et al. | — | 2023 | → |
| Modeling Cellular Crosstalk of Neuroinflammation Axis by Tri-cultures of iPSC-Derived Human Microglia, Astrocytes, and Neurons. | Connolly K et al. | — | 2023 | → |
| Modeling congenital brain malformations with brain organoids: a narrative review. | Ji XS et al. | — | 2023 | → |
| Modeling nervous system tumors with human stem cells and organoids. | Duan J et al. | — | 2023 | → |
| Moderate intrinsic phenotypic alterations in <i>C9orf72</i> ALS/FTD iPSC-microglia despite the presence of C9orf72 pathological features. | Lorenzini I et al. | — | 2023 | → |
| Molecular Insights into Cell Type-specific Roles in Alzheimer's Disease: Human Induced Pluripotent Stem Cell-based Disease Modelling. | Qu W et al. | — | 2023 | → |
| Neural lineage differentiation of human pluripotent stem cells: Advances in disease modeling. | Yan YW et al. | — | 2023 | → |
| Neurodegeneration cell per cell. | Balusu S et al. | — | 2023 | → |
| 'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell-derived immune cells. | Wang C et al. | — | 2023 | → |
| Opportunities and limitations for studying neuropsychiatric disorders using patient-derived induced pluripotent stem cells. | Hong Y et al. | — | 2023 | → |
| Organoids for modeling prion diseases. | Walters RO et al. | — | 2023 | → |
| Potential use of iPSCs for disease modeling, drug screening, and cell-based therapy for Alzheimer's disease. | Marei HE et al. | — | 2023 | → |
| Pushing the boundaries of brain organoids to study Alzheimer's disease. | Cerneckis J et al. | — | 2023 | → |
| Quinolinate promotes macrophage-induced immune tolerance in glioblastoma through the NMDAR/PPARγ signaling axis. | Kesarwani P et al. | — | 2023 | → |
| Recent Advances in Brain Organoid Technology for Human Brain Research. | Jeong E et al. | — | 2023 | → |
| Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders. | Dutan Polit L et al. | — | 2023 | → |
| Reenacting Neuroectodermal Exposure of Hematopoietic Progenitors Enables Scalable Production of Cryopreservable iPSC-Derived Human Microglia. | Mathews M et al. | — | 2023 | → |
| Regulation of synaptic connectivity in schizophrenia spectrum by mutual neuron-microglia interaction. | Breitmeyer R et al. | — | 2023 | → |
| Retinal organoids from human-induced pluripotent stem cells: From studying retinal dystrophies to early diagnosis of Alzheimer's and Parkinson's disease. | Móvio MI et al. | — | 2023 | → |
| Role of NCKAP1 in the Defective Phagocytic Function of Microglia-Like Cells Derived from Rapidly Progressing Sporadic ALS. | Noh MY et al. | — | 2023 | → |
| Single Systemic Administration of a Gene Therapy Leading to Disease Treatment in Metachromatic Leukodystrophy <i>Arsa</i> Knock-Out Mice. | St Martin T et al. | — | 2023 | → |
| Species-specific metabolic reprogramming in human and mouse microglia during inflammatory pathway induction. | Sabogal-Guáqueta AM et al. | — | 2023 | → |
| Stem Cell-Based Organoid Models of Neurodevelopmental Disorders. | Wang L et al. | — | 2023 | → |
| Strategies for Manipulating Microglia to Determine Their Role in the Healthy and Diseased Brain. | Parajuli B et al. | — | 2023 | → |
| Systematic comparison of culture media uncovers phenotypic shift of primary human microglia defined by reduced reliance to CSF1R signaling. | Dorion MF et al. | — | 2023 | → |
| The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells. | Cai W et al. | — | 2023 | → |
| The Breakthroughs and Caveats of Using Human Pluripotent Stem Cells in Modeling Alzheimer's Disease. | Sahlgren Bendtsen KM et al. | — | 2023 | → |
| The Generation and Functional Characterization of Human Microglia-Like Cells Derived from iPS and Embryonic Stem Cells. | Lehoux M et al. | — | 2023 | → |
| The Interplay between α-Synuclein and Microglia in α-Synucleinopathies. | Deyell JS et al. | — | 2023 | → |
| The Multifaceted Role of WNT Signaling in Alzheimer's Disease Onset and Age-Related Progression. | Kostes WW et al. | — | 2023 | → |
| Three-Dimensional Cell Cultures: The Bridge between In Vitro and In Vivo Models. | Urzì O et al. | — | 2023 | → |
| Tools for studying human microglia: In vitro and in vivo strategies. | Warden AS et al. | — | 2023 | → |
| Tracking human neurologic disease status in mouse brain/plasma using reporter-tagged, EV-associated biomarkers. | Maalouf KE et al. | — | 2023 | → |
| Transcriptional and epigenetic regulation of microglia in substance use disorders. | Vilca SJ et al. | — | 2023 | → |
| Transplantation Strategies to Enhance Maturity and Cellular Complexity in Brain Organoids. | Wang M et al. | — | 2023 | → |
| Transplanting Microglia for Treating CNS Injuries and Neurological Diseases and Disorders, and Prospects for Generating Exogenic Microglia. | Var SR et al. | — | 2023 | → |
| Understanding neural development and diseases using CRISPR screens in human pluripotent stem cell-derived cultures. | Ahmed M et al. | — | 2023 | → |
| Unlocking Neural Function with 3D In Vitro Models: A Technical Review of Self-Assembled, Guided, and Bioprinted Brain Organoids and Their Applications in the Study of Neurodevelopmental and Neurodegenerative Disorders. | D'Antoni C et al. | — | 2023 | → |
| Use of <i>in vitro</i> derived human neuronal models to study host-parasite interactions of <i>Toxoplasma gondii</i> in neurons and neuropathogenesis of chronic toxoplasmosis. | Halonen SK | — | 2023 | → |
| Using Human-Induced Pluripotent Stem Cell Derived Neurons on Microelectrode Arrays to Model Neurological Disease: A Review. | Lv S et al. | — | 2023 | → |
| Using Stems to Bear Fruit: Deciphering the Role of Alzheimer's Disease Risk Loci in Human-Induced Pluripotent Stem Cell-Derived Microglia. | Wickstead ES | — | 2023 | → |
| A CRISPRi/a platform in human iPSC-derived microglia uncovers regulators of disease states. | Dräger NM et al. | — | 2022 | → |
| Across Dimensions: Developing 2D and 3D Human iPSC-Based Models of Fragile X Syndrome. | Lee A et al. | — | 2022 | → |
| Advanced in vitro models: Microglia in action. | Cakir B et al. | — | 2022 | → |
| Advances in Recapitulating Alzheimer's Disease Phenotypes Using Human Induced Pluripotent Stem Cell-Based In Vitro Models. | Hasan MF et al. | — | 2022 | → |
| Advancing basic and translational research to deepen understanding of the molecular immune-mediated mechanisms regulating long-term persistence of HIV-1 in microglia in the adult human brain. | Boucher T et al. | — | 2022 | → |
| Alpha retinal ganglion cells in pigmented mice retina: number and distribution. | Gallego-Ortega A et al. | — | 2022 | → |
| Animal and Cellular Models of Alzheimer's Disease: Progress, Promise, and Future Approaches. | Trujillo-Estrada L et al. | — | 2022 | → |
| Animal models for studies of HIV-1 brain reservoirs. | Waight E et al. | — | 2022 | → |
| Assaying Microglia Functions In Vitro. | Maguire E et al. | — | 2022 | → |
| Assessing human iPSC-derived microglia identity and function by immunostaining, phagocytosis, calcium activity, and inflammation assay. | Hübschmann V et al. | — | 2022 | → |
| Association of a common genetic variant with Parkinson's disease is mediated by microglia. | Langston RG et al. | — | 2022 | → |
| A systematic characterization of microglia-like cell occurrence during retinal organoid differentiation. | Bartalska K et al. | — | 2022 | → |
| A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease. | Zhao P et al. | — | 2022 | → |
| Bilirubin-Induced Neurological Damage: Current and Emerging iPSC-Derived Brain Organoid Models. | Pranty AI et al. | — | 2022 | → |
| Building in vitro models of the brain to understand the role of <i>APOE</i> in Alzheimer's disease. | Pinals RL et al. | — | 2022 | → |
| Cellular Models of Alpha-Synuclein Aggregation: What Have We Learned and Implications for Future Study. | Albert K et al. | — | 2022 | → |
| Characterization of HIV-1 Infection in Microglia-Containing Human Cerebral Organoids. | Gumbs SBH et al. | — | 2022 | → |
| Characterization of Macrophage-Tropic HIV-1 Infection of Central Nervous System Cells and the Influence of Inflammation. | Woodburn BM et al. | — | 2022 | → |
| Chiral nanomaterials for biosensing, bioimaging, and disease therapies. | Qu A et al. | — | 2022 | → |
| Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. | Tcw J et al. | — | 2022 | → |
| Comparing the Characteristics of Microglia Preparations Generated Using Different Human iPSC-Based Differentiation Methods to Model Neurodegenerative Diseases. | Tang YM et al. | — | 2022 | → |
| Cortical Organoids to Model Microcephaly. | Farcy S et al. | — | 2022 | → |
| Current advancements of modelling schizophrenia using patient-derived induced pluripotent stem cells. | Dubonyte U et al. | — | 2022 | → |
| Deterministic programming of human pluripotent stem cells into microglia facilitates studying their role in health and disease. | Speicher AM et al. | — | 2022 | → |
| Direct Conversion to Achieve Glial Cell Fates: Oligodendrocytes and Schwann Cells. | Yun W et al. | — | 2022 | → |
| Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. | Zhao P et al. | — | 2022 | → |
| Disease Modeling of Neurodegenerative Disorders Using Direct Neural Reprogramming. | Legault EM et al. | — | 2022 | → |
| Dissecting the complexities of Alzheimer disease with in vitro models of the human brain. | Blanchard JW et al. | — | 2022 | → |
| Distinct SARS-CoV-2 RNA fragments activate Toll-like receptors 7 and 8 and induce cytokine release from human macrophages and microglia. | Wallach T et al. | — | 2022 | → |
| Efficient and Easy Conversion of Human iPSCs into Functional Induced Microglia-like Cells. | Lanfer J et al. | — | 2022 | → |
| Emerging Role of miR-21-5p in Neuron-Glia Dysregulation and Exosome Transfer Using Multiple Models of Alzheimer's Disease. | Garcia G et al. | — | 2022 | → |
| Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. | Edavettal S et al. | — | 2022 | → |
| Evaluation of a Selective Chemical Probe Validates That CK2 Mediates Neuroinflammation in a Human Induced Pluripotent Stem Cell-Derived Microglial Model. | Mishra S et al. | — | 2022 | → |
| Expression of the transcription factor PU.1 induces the generation of microglia-like cells in human cortical organoids. | Cakir B et al. | — | 2022 | → |
| Functional microglia derived from human pluripotent stem cells empower retinal organ. | Gao ML et al. | — | 2022 | → |
| Getting the right cells. | Cakir B et al. | — | 2022 | → |
| Harnessing cerebral organoids for Alzheimer's disease research. | Bubnys A et al. | — | 2022 | → |
| Homozygous ALS-linked FUS P525L mutations cell- autonomously perturb transcriptome profile and chemoreceptor signaling in human iPSC microglia. | Kerk SY et al. | — | 2022 | → |
| Human Brain-Based Models Provide a Powerful Tool for the Advancement of Parkinson's Disease Research and Therapeutic Development. | McComish SF et al. | — | 2022 | → |
| Human-Induced Pluripotent Stem Cell-Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases. | Kiris E | — | 2022 | → |
| Human Induced Pluripotent Stem Cell-Derived Microglia (hiPSC-Microglia). | McQuade A et al. | — | 2022 | → |
| Human iPSC co-culture model to investigate the interaction between microglia and motor neurons. | Vahsen BF et al. | — | 2022 | → |
| Human iPSC-Derived Neural Models for Studying Alzheimer's Disease: from Neural Stem Cells to Cerebral Organoids. | Barak M et al. | — | 2022 | → |
| Human microglial models to study HIV infection and neuropathogenesis: a literature overview and comparative analyses. | Gumbs SBH et al. | — | 2022 | → |
| Human neural cell type-specific extracellular vesicle proteome defines disease-related molecules associated with activated astrocytes in Alzheimer's disease brain. | You Y et al. | — | 2022 | → |
| Human Pluripotent Stem Cell Differentiation to Microglia. | Ijaz L et al. | — | 2022 | → |
| Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation. | Giacomelli E et al. | — | 2022 | → |
| Improving mouse models for the study of Alzheimer's disease. | Reagan AM et al. | — | 2022 | → |
| Induced pluripotent stem cell-based organ-on-a-chip as personalized drug screening tools: A focus on neurodegenerative disorders. | Fanizza F et al. | — | 2022 | → |
| Intratarget Microdosing for Deep Phenotyping of Multiple Drug Effects in the Live Brain. | Kim J et al. | — | 2022 | → |
| In Vitro Methodologies to Study the Role of Advanced Glycation End Products (AGEs) in Neurodegeneration. | Chrysanthou M et al. | — | 2022 | → |
| Iron accumulation induces oxidative stress, while depressing inflammatory polarization in human iPSC-derived microglia. | Kenkhuis B et al. | — | 2022 | → |
| Leveraging the Genetic Diversity of Human Stem Cells in Therapeutic Approaches. | Tegtmeyer M et al. | — | 2022 | → |
| LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions. | Zhao P et al. | — | 2022 | → |
| Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity. | Victor MB et al. | — | 2022 | → |
| Lithium inhibits tryptophan catabolism via the inflammation-induced kynurenine pathway in human microglia. | Göttert R et al. | — | 2022 | → |
| Loss of TREM2 rescues hyperactivation of microglia, but not lysosomal deficits and neurotoxicity in models of progranulin deficiency. | Reifschneider A et al. | — | 2022 | → |
| Microglia and Astrocyte Function and Communication: What Do We Know in Humans? | Garland EF et al. | — | 2022 | → |
| Microglia in a Dish-Which Techniques Are on the Menu for Functional Studies? | Aktories P et al. | — | 2022 | → |
| Microglia integration into human midbrain organoids leads to increased neuronal maturation and functionality. | Sabate-Soler S et al. | — | 2022 | → |
| Microglial amyloid beta clearance is driven by PIEZO1 channels. | Jäntti H et al. | — | 2022 | → |
| Microglial TREM2 in amyotrophic lateral sclerosis. | Xie M et al. | — | 2022 | → |
| Microglia Phenotypes in Aging and Neurodegenerative Diseases. | Wendimu MY et al. | — | 2022 | → |
| Modeling and Targeting Neuroglial Interactions with Human Pluripotent Stem Cell Models. | Bigarreau J et al. | — | 2022 | → |
| Modeling Developmental Brain Diseases Using Human Pluripotent Stem Cells-Derived Brain Organoids - Progress and Perspective. | Bhattacharya A et al. | — | 2022 | → |
| Modeling infectious diseases of the central nervous system with human brain organoids. | Priyathilaka TT et al. | — | 2022 | → |
| Neuroimmune contributions to Alzheimer's disease: a focus on human data. | Haage V et al. | — | 2022 | → |
| Organoid transduction using recombinant adeno-associated viral vectors: Challenges and opportunities. | Belova L et al. | — | 2022 | → |
| Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives. | Youhanna S et al. | — | 2022 | → |
| Pathogenesis, therapeutic strategies and biomarker development based on "omics" analysis related to microglia in Alzheimer's disease. | Gao C et al. | — | 2022 | → |
| Patient-Derived In Vitro Models of Microglial Function and Synaptic Engulfment in Schizophrenia. | Sheridan SD et al. | — | 2022 | → |
| Patient-Specific iPSCs-Based Models of Neurodegenerative Diseases: Focus on Aberrant Calcium Signaling. | Grekhnev DA et al. | — | 2022 | → |
| Pluripotent stem cell strategies for rebuilding the human brain. | Limone F et al. | — | 2022 | → |
| Proficiency of Extracellular Vesicles From hiPSC-Derived Neural Stem Cells in Modulating Proinflammatory Human Microglia: Role of Pentraxin-3 and miRNA-21-5p. | Upadhya R et al. | — | 2022 | → |
| Promising Strategies for the Development of Advanced In Vitro Models with High Predictive Power in Ischaemic Stroke Research. | Van Breedam E et al. | — | 2022 | → |
| Proteomic Alterations and Novel Markers of Neurotoxic Reactive Astrocytes in Human Induced Pluripotent Stem Cell Models. | Labib D et al. | — | 2022 | → |
| Quality criteria for in vitro human pluripotent stem cell-derived models of tissue-based cells. | Pistollato F et al. | — | 2022 | → |
| Recent Advances in Microglia Modelling to Address Translational Outcomes in Neurodegenerative Diseases. | Cuní-López C et al. | — | 2022 | → |
| Redefining microglia states: Lessons and limits of human and mouse models to study microglia states in neurodegenerative diseases. | Yvanka de Soysa T et al. | — | 2022 | → |
| Region Specific Brain Organoids to Study Neurodevelopmental Disorders. | Susaimanickam PJ et al. | — | 2022 | → |
| Replacement of Mouse Microglia With Human Induced Pluripotent Stem Cell (hiPSC)-Derived Microglia in Mouse Organotypic Slice Cultures. | Ogaki A et al. | — | 2022 | → |
| Research models of neurodevelopmental disorders: The right model in the right place. | Damianidou E et al. | — | 2022 | → |
| Retroviral infection of human neurospheres and use of stem Cell EVs to repair cellular damage. | Branscome H et al. | — | 2022 | → |
| Single-cell transcriptomics defines an improved, validated monoculture protocol for differentiation of human iPSC to microglia. | Washer SJ et al. | — | 2022 | → |
| Single transcription factor efficiently leads human induced pluripotent stem cells to functional microglia. | Sonn I et al. | — | 2022 | → |
| Synthetic amyloid beta does not induce a robust transcriptional response in innate immune cell culture systems. | Quiroga IY et al. | — | 2022 | → |
| The Application of Brain Organoids in Assessing Neural Toxicity. | Fan P et al. | — | 2022 | → |
| The Future of 3D Brain Cultures in Developmental Neurotoxicity Testing. | Hogberg HT et al. | — | 2022 | → |
| The role of neural stem cells in regulating glial scar formation and repair. | Nicaise AM et al. | — | 2022 | → |
| Tissue-Engineered Models of the Human Brain: State-of-the-Art Analysis and Challenges. | Tarricone G et al. | — | 2022 | → |
| TREM2 regulates purinergic receptor-mediated calcium signaling and motility in human iPSC-derived microglia. | Jairaman A et al. | — | 2022 | → |
| Type-I-interferon signaling drives microglial dysfunction and senescence in human iPSC models of Down syndrome and Alzheimer's disease. | Jin M et al. | — | 2022 | → |
| Using 2D and 3D pluripotent stem cell models to study neurotropic viruses. | LaNoce E et al. | — | 2022 | → |
| Using MS induced pluripotent stem cells to investigate MS aetiology. | Fortune AJ et al. | — | 2022 | → |
| Using Stem Cell Models to Explore the Genetics Underlying Psychiatric Disorders: Linking Risk Variants, Genes, and Biology in Brain Disease. | Brennand KJ | — | 2022 | → |
| 3D Bioprinting of Neural Tissues. | Cadena M et al. | — | 2021 | → |
| 3D hydrogel models of the neurovascular unit to investigate blood-brain barrier dysfunction. | Potjewyd G et al. | — | 2021 | → |
| A 3D cell culture approach for studying neuroinflammation. | Carroll JA et al. | — | 2021 | → |
| A Cerebral Organoid Connectivity Apparatus to Model Neuronal Tract Circuitry. | Robles DA et al. | — | 2021 | → |
| A Core Transcription Regulatory Circuitry Defining Microglia Cell Identity Inferred from the Reanalysis of Multiple Human Microglia Differentiation Protocols. | Aubert A et al. | — | 2021 | → |
| Advances in Central Nervous System Organoids: A Focus on Organoid-Based Models for Motor Neuron Disease. | Vieira de Sá R et al. | — | 2021 | → |
| Aged Microglia in Neurodegenerative Diseases: Microglia Lifespan and Culture Methods. | Yoo HJ et al. | — | 2021 | → |
| Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. | Lucido MJ et al. | — | 2021 | → |
| A map of transcriptional heterogeneity and regulatory variation in human microglia. | Young AMH et al. | — | 2021 | → |
| A new method for obtaining bankable and expandable adult-like microglia in mice. | You MJ et al. | — | 2021 | → |
| An integrated analysis of human myeloid cells identifies gaps in in vitro models of in vivo biology. | Rajab N et al. | — | 2021 | → |
| Application of the Pluripotent Stem Cells and Genomics in Cardiovascular Research-What We Have Learnt and Not Learnt until Now. | Simeon M et al. | — | 2021 | → |
| Applications of brain organoids in neurodevelopment and neurological diseases. | Sun N et al. | — | 2021 | → |
| A State-of-the-Art of Functional Scaffolds for 3D Nervous Tissue Regeneration. | Tupone MG et al. | — | 2021 | → |
| Astrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models. | Franklin H et al. | — | 2021 | → |
| A Subpopulation of Microglia Generated in the Adult Mouse Brain Originates from Prominin-1-Expressing Progenitors. | Prater KE et al. | — | 2021 | → |
| Brain organoids: an ensemble of bioassays to investigate human neurodevelopment and disease. | Sidhaye J et al. | — | 2021 | → |
| Brain organoids: A new frontier of human neuroscience research. | Lancaster MA | — | 2021 | → |
| Brain Organoids: Filling the Need for a Human Model of Neurological Disorder. | Jalink P et al. | — | 2021 | → |
| Brain Organoids: Studying Human Brain Development and Diseases in a Dish. | Xu J et al. | — | 2021 | → |
| Building on a Solid Foundation: Adding Relevance and Reproducibility to Neurological Modeling Using Human Pluripotent Stem Cells. | Knock E et al. | — | 2021 | → |
| Building the brain from scratch: Engineering region-specific brain organoids from human stem cells to study neural development and disease. | Jacob F et al. | — | 2021 | → |
| Cell-Type-Specific High Throughput Toxicity Testing in Human Midbrain Organoids. | Renner H et al. | — | 2021 | → |
| Cellular complexity in brain organoids: Current progress and unsolved issues. | Mansour AA et al. | — | 2021 | → |
| Cerebral organoids as a new model for prion disease. | Groveman BR et al. | — | 2021 | → |
| Classic and new mediators for in vitro modelling of human macrophages. | Luque-Martin R et al. | — | 2021 | → |
| Co-Culturing Microglia and Cortical Neurons Differentiated from Human Induced Pluripotent Stem Cells. | Lopez-Lengowski K et al. | — | 2021 | → |
| Combining Automated Organoid Workflows with Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond. | Renner H et al. | — | 2021 | → |
| Comparative Review of Microglia and Monocytes in CNS Phagocytosis. | Andoh M et al. | — | 2021 | → |
| Complex Organ Construction from Human Pluripotent Stem Cells for Biological Research and Disease Modeling with New Emerging Techniques. | Matsumoto R et al. | — | 2021 | → |
| Contribution of Human Pluripotent Stem Cell-Based Models to Drug Discovery for Neurological Disorders. | Benchoua A et al. | — | 2021 | → |
| Current status and future prospects of patient-derived induced pluripotent stem cells. | Wang Z et al. | — | 2021 | → |
| Current tools to interrogate microglial biology. | Dumas AA et al. | — | 2021 | → |
| Deconstructing and reconstructing the human brain with regionally specified brain organoids. | Xiang Y et al. | — | 2021 | → |
| Detection and Functional Evaluation of the P2X7 Receptor in hiPSC Derived Neurons and Microglia-Like Cells. | Francistiová L et al. | — | 2021 | → |
| Developing human pluripotent stem cell-based cerebral organoids with a controllable microglia ratio for modeling brain development and pathology. | Xu R et al. | — | 2021 | → |
| Differentiation of human induced pluripotent stem cells to authentic macrophages using a defined, serum-free, open-source medium. | Vaughan-Jackson A et al. | — | 2021 | → |
| Dissecting Alzheimer's disease pathogenesis in human 2D and 3D models. | Cenini G et al. | — | 2021 | → |
| Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells. | Pons-Espinal M et al. | — | 2021 | → |
| Efficient conversion of human induced pluripotent stem cells into microglia by defined transcription factors. | Chen SW et al. | — | 2021 | → |
| Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases. | Trudler D et al. | — | 2021 | → |
| Evolutionary conservation and divergence of the human brain transcriptome. | Pembroke WG et al. | — | 2021 | → |
| Evolving Models and Tools for Microglial Studies in the Central Nervous System. | Zhang Y et al. | — | 2021 | → |
| Exploiting dynamic enhancer landscapes to decode macrophage and microglia phenotypes in health and disease. | Troutman TD et al. | — | 2021 | → |
| Expression of HIV-1 Intron-Containing RNA in Microglia Induces Inflammatory Responses. | Akiyama H et al. | — | 2021 | → |
| From Brain Organoids to Networking Assembloids: Implications for Neuroendocrinology and Stress Medicine. | Makrygianni EA et al. | — | 2021 | → |
| From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease. | Outeiro TF et al. | — | 2021 | → |
| Fully defined human pluripotent stem cell-derived microglia and tri-culture system model C3 production in Alzheimer's disease. | Guttikonda SR et al. | — | 2021 | → |
| Generation of cryopreserved macrophages from normal and genetically engineered human pluripotent stem cells for disease modelling. | Munn C et al. | — | 2021 | → |
| Genome Editing in iPSC-Based Neural Systems: From Disease Models to Future Therapeutic Strategies. | McTague A et al. | — | 2021 | → |
| Growing Glia: Cultivating Human Stem Cell Models of Gliogenesis in Health and Disease. | Lanjewar SN et al. | — | 2021 | → |
| Human iPSC-Derived Glia as a Tool for Neuropsychiatric Research and Drug Development. | Heider J et al. | — | 2021 | → |
| Human microglia states are conserved across experimental models and regulate neural stem cell responses in chimeric organoids. | Popova G et al. | — | 2021 | → |
| Human stem cell models to study host-virus interactions in the central nervous system. | Harschnitz O et al. | — | 2021 | → |
| Improved modeling of human AD with an automated culturing platform for iPSC neurons, astrocytes and microglia. | Bassil R et al. | — | 2021 | → |
| Integration of Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. | Novikova G et al. | — | 2021 | → |
| Involvement of Microglia in the Pathophysiology of Intracranial Aneurysms and Vascular Malformations-A Short Overview. | Timis TL et al. | — | 2021 | → |
| iPSC-derived myelinoids to study myelin biology of humans. | James OG et al. | — | 2021 | → |
| Live Viral Vaccine Neurovirulence Screening: Current and Future Models. | May Fulton C et al. | — | 2021 | → |
| Metabolic and immune dysfunction of glia in neurodegenerative disorders: Focus on iPSC models. | Rõlova T et al. | — | 2021 | → |
| Methodologies for Generating Brain Organoids to Model Viral Pathogenesis in the CNS. | Hopkins HK et al. | — | 2021 | → |
| Microglia and Central Nervous System-Associated Macrophages-From Origin to Disease Modulation. | Prinz M et al. | — | 2021 | → |
| Microglia Development and Maturation and Its Implications for Induction of Microglia-Like Cells from Human iPSCs. | Wurm J et al. | — | 2021 | → |
| Microglia: Immune and non-immune functions. | Borst K et al. | — | 2021 | → |
| Microglia in Alzheimer's disease at single-cell level. Are there common patterns in humans and mice? | Chen Y et al. | — | 2021 | → |
| Microglia-like Cells Promote Neuronal Functions in Cerebral Organoids. | Fagerlund I et al. | — | 2021 | → |
| Microglial innate memory and epigenetic reprogramming in neurological disorders. | Martins-Ferreira R et al. | — | 2021 | → |
| Microglial Turnover in Ageing-Related Neurodegeneration: Therapeutic Avenue to Intervene in Disease Progression. | Azam S et al. | — | 2021 | → |
| Microglia modulate neurodevelopment in human neuroimmune organoids. | Bennett ML et al. | — | 2021 | → |
| Modeling Neurodevelopmental and Neuropsychiatric Diseases with Astrocytes Derived from Human-Induced Pluripotent Stem Cells. | Ren B et al. | — | 2021 | → |
| Modeling Neurological Disorders in 3D Organoids Using Human-Derived Pluripotent Stem Cells. | Bose R et al. | — | 2021 | → |
| Modeling Traumatic Brain Injury in Human Cerebral Organoids. | Ramirez S et al. | — | 2021 | → |
| Modelling neurodegenerative disease using brain organoids. | Wray S | — | 2021 | → |
| Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. | Drobny A et al. | — | 2021 | → |
| Multifaceted involvement of microglia in gray matter pathology in multiple sclerosis. | Tsouki F et al. | — | 2021 | → |
| Murine induced pluripotent stem cell-derived neuroimmune cell culture models emphasize opposite immune-effector functions of interleukin 13-primed microglia and macrophages in terms of neuroimmune toxicity. | Quarta A et al. | — | 2021 | → |
| Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia. | Mamais A et al. | — | 2021 | → |
| Neural In Vitro Models for Studying Substances Acting on the Central Nervous System. | Fritsche E et al. | — | 2021 | → |
| Neuroinflammatory <i>In Vitro</i> Cell Culture Models and the Potential Applications for Neurological Disorders. | Peng Y et al. | — | 2021 | → |
| Neurons derived from human-induced pluripotent stem cells express mu and kappa opioid receptors. | Ju ZH et al. | — | 2021 | → |
| Next-Generation Human Cerebral Organoids as Powerful Tools To Advance NeuroHIV Research. | Premeaux TA et al. | — | 2021 | → |
| Novel Scalable and Simplified System to Generate Microglia-Containing Cerebral Organoids From Human Induced Pluripotent Stem Cells. | Bodnar B et al. | — | 2021 | → |
| Novel test strategies for in vitro seizure liability assessment. | Tukker AM et al. | — | 2021 | → |
| Oligodendrocytes and Microglia: Key Players in Myelin Development, Damage and Repair. | Kalafatakis I et al. | — | 2021 | → |
| Phenotyping Neurodegeneration in Human iPSCs. | Li J et al. | — | 2021 | → |
| Physiology of Cultured Human Microglia Maintained in a Defined Culture Medium. | Tewari M et al. | — | 2021 | → |
| Protocol for controlled cortical impact in human cerebral organoids to model traumatic brain injury. | Ramirez S et al. | — | 2021 | → |
| PsychENCODE and beyond: transcriptomics and epigenomics of brain development and organoids. | Jourdon A et al. | — | 2021 | → |
| Redefining Microglial Identity in Health and Disease at Single-Cell Resolution. | Provenzano F et al. | — | 2021 | → |
| Reduced TREM2 activation in microglia of patients with Alzheimer's disease. | Okuzono Y et al. | — | 2021 | → |
| Regional specification and complementation with non-neuroectodermal cells in human brain organoids. | Tanaka Y et al. | — | 2021 | → |
| Roles of microglia in Alzheimer's disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention. | Takata K et al. | — | 2021 | → |
| Skin organoids: A new human model for developmental and translational research. | Lee J et al. | — | 2021 | → |
| Sodium P-aminosalicylic Acid Attenuates Manganese-Induced Neuroinflammation in BV2 Microglia by Modulating NF-κB Pathway. | Li J et al. | — | 2021 | → |
| Soluble α-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. | Trudler D et al. | — | 2021 | → |
| Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors. | Lagomarsino VN et al. | — | 2021 | → |
| Strategies and Tools for Studying Microglial-Mediated Synapse Elimination and Refinement. | Morini R et al. | — | 2021 | → |
| Tackling neurodegenerative diseases with genomic engineering: A new stem cell initiative from the NIH. | Ramos DM et al. | — | 2021 | → |
| The application of in vitro-derived human neurons in neurodegenerative disease modeling. | D'Souza GX et al. | — | 2021 | → |
| The CD22-IGF2R interaction is a therapeutic target for microglial lysosome dysfunction in Niemann-Pick type C. | Pluvinage JV et al. | — | 2021 | → |
| The Effects of Environmental Adversities on Human Neocortical Neurogenesis Modeled in Brain Organoids. | Sarieva K et al. | — | 2021 | → |
| The emerging tale of microglia in psychiatric disorders. | Rahimian R et al. | — | 2021 | → |
| The human bone marrow harbors a CD45<sup>-</sup> CD11B<sup>+</sup> cell progenitor permitting rapid microglia-like cell derivative approaches. | Bruzelius A et al. | — | 2021 | → |
| The influence of the R47H triggering receptor expressed on myeloid cells 2 variant on microglial exosome profiles. | Mallach A et al. | — | 2021 | → |
| The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. | MacDougall G et al. | — | 2021 | → |
| The Potential of Induced Pluripotent Stem Cells to Treat and Model Alzheimer's Disease. | Schulz JM | — | 2021 | → |
| Three-dimensional in vitro tissue culture models of brain organoids. | Gong J et al. | — | 2021 | → |
| Three-dimensional model of glioblastoma by co-culturing tumor stem cells with human brain organoids. | Azzarelli R et al. | — | 2021 | → |
| Towards Advanced iPSC-based Drug Development for Neurodegenerative Disease. | Pasteuning-Vuhman S et al. | — | 2021 | → |
| Toxoplasma gondii infection and its implications within the central nervous system. | Matta SK et al. | — | 2021 | → |
| Transcriptional signature in microglia associated with Aβ plaque phagocytosis. | Grubman A et al. | — | 2021 | → |
| Transnasal transplantation of human induced pluripotent stem cell-derived microglia to the brain of immunocompetent mice. | Parajuli B et al. | — | 2021 | → |
| Tubular human brain organoids to model microglia-mediated neuroinflammation. | Ao Z et al. | — | 2021 | → |
| Unraveling Human Brain Development and Evolution Using Organoid Models. | Fernandes S et al. | — | 2021 | → |
| Using multi-organ culture systems to study Parkinson's disease. | Reiner O et al. | — | 2021 | → |
| Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia. | Albert K et al. | — | 2021 | → |
| Validation of Induced Microglia-Like Cells (iMG Cells) for Future Studies of Brain Diseases. | Banerjee A et al. | — | 2021 | → |
| WWOX-Related Neurodevelopmental Disorders: Models and Future Perspectives. | Steinberg DJ et al. | — | 2021 | → |
| 3D Brain Organoids: Studying Brain Development and Disease Outside the Embryo. | Velasco S et al. | — | 2020 | → |
| 3D brain tissue physiological model with co-cultured primary neurons and glial cells in hydrogels. | Raimondi I et al. | — | 2020 | → |
| A Bump-Hole Strategy for Increased Stringency of Cell-Specific Metabolic Labeling of RNA. | Nguyen K et al. | — | 2020 | → |
| A characterization of the molecular phenotype and inflammatory response of schizophrenia patient-derived microglia-like cells. | Ormel PR et al. | — | 2020 | → |
| A CX3CR1 Reporter hESC Line Facilitates Integrative Analysis of In-Vitro-Derived Microglia and Improved Microglia Identity upon Neuron-Glia Co-culture. | Grubman A et al. | — | 2020 | → |
| A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids. | Renner H et al. | — | 2020 | → |
| A locked immunometabolic switch underlies TREM2 R47H loss of function in human iPSC-derived microglia. | Piers TM et al. | — | 2020 | → |
| Alzheimer's Risk Gene TREM2 Determines Functional Properties of New Type of Human iPSC-Derived Microglia. | Reich M et al. | — | 2020 | → |
| Brain organoids for the study of human neurobiology at the interface of in vitro and in vivo. | Chiaradia I et al. | — | 2020 | → |
| Brain Organoids: Human Neurodevelopment in a Dish. | Benito-Kwiecinski S et al. | — | 2020 | → |
| Brain Parenchymal and Extraparenchymal Macrophages in Development, Homeostasis, and Disease. | Brioschi S et al. | — | 2020 | → |
| Building a Human Brain for Research. | Bitar M et al. | — | 2020 | → |
| CELF2 regulates the species-specific alternative splicing of TREM2. | Yanaizu M et al. | — | 2020 | → |
| Cell Type-Specific In Vitro Gene Expression Profiling of Stem Cell-Derived Neural Models. | Gregory JA et al. | — | 2020 | → |
| Cerebral organoids: emerging ex vivo humanoid models of glioblastoma. | Papaioannou MD et al. | — | 2020 | → |
| Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome. | Lee SE et al. | — | 2020 | → |
| CIRM tools and technologies: Breaking bottlenecks to the development of stem cell therapies. | Collins LR et al. | — | 2020 | → |
| Comparative analysis of human microglial models for studies of HIV replication and pathogenesis. | Rai MA et al. | — | 2020 | → |
| CRISPR-based functional genomics for neurological disease. | Kampmann M | — | 2020 | → |
| Determinants of Resident Tissue Macrophage Identity and Function. | Blériot C et al. | — | 2020 | → |
| Efficient Strategies for Microglia Replacement in the Central Nervous System. | Xu Z et al. | — | 2020 | → |
| Emerging Developments in Human Induced Pluripotent Stem Cell-Derived Microglia: Implications for Modelling Psychiatric Disorders With a Neurodevelopmental Origin. | Hanger B et al. | — | 2020 | → |
| Emerging technologies to study glial cells. | Hirbec H et al. | — | 2020 | → |
| Functional analysis of CX3CR1 in human induced pluripotent stem (iPS) cell-derived microglia-like cells. | Murai N et al. | — | 2020 | → |
| Functional genomics, genetic risk profiling and cell phenotypes in neurodegenerative disease. | Finkbeiner S | — | 2020 | → |
| Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer's disease. | McQuade A et al. | — | 2020 | → |
| Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. | Jacob F et al. | — | 2020 | → |
| Genetic architecture of Alzheimer's disease. | Neuner SM et al. | — | 2020 | → |
| Hallmarks of NLRP3 inflammasome activation are observed in organotypic hippocampal slice culture. | Hoyle C et al. | — | 2020 | → |
| High-Fidelity Modeling of Human Microglia with Pluripotent Stem Cells. | Jiang P et al. | — | 2020 | → |
| HIV-1 Persistence and Chronic Induction of Innate Immune Responses in Macrophages. | Akiyama H et al. | — | 2020 | → |
| Honing the Double-Edged Sword: Improving Human iPSC-Microglia Models. | Hedegaard A et al. | — | 2020 | → |
| Human Induced Pluripotent Stem Cell-Derived Neural Cells from Alzheimer's Disease Patients Exhibited Different Susceptibility to Oxidative Stress. | Zhang L et al. | — | 2020 | → |
| Human-induced pluripotent stem cells as a model for studying sporadic Alzheimer's disease. | Riemens RJM et al. | — | 2020 | → |
| Human in vitro models for understanding mechanisms of autism spectrum disorder. | Gordon A et al. | — | 2020 | → |
| Human iPSC-derived mature microglia retain their identity and functionally integrate in the chimeric mouse brain. | Xu R et al. | — | 2020 | → |
| Human iPSC-derived microglia: A growing toolset to study the brain's innate immune cells. | Hasselmann J et al. | — | 2020 | → |
| Human macrophages and innate lymphoid cells: Tissue-resident innate immunity in humanized mice. | Alisjahbana A et al. | — | 2020 | → |
| Human organoids to model the developing human neocortex in health and disease. | Khakipoor S et al. | — | 2020 | → |
| Human Pluripotent Stem Cell-Derived Neural Cells as a Relevant Platform for Drug Screening in Alzheimer's Disease. | Garcia-Leon JA et al. | — | 2020 | → |
| Immovable Object Meets Unstoppable Force? Dialogue Between Resident and Peripheral Myeloid Cells in the Inflamed Brain. | Spiteri AG et al. | — | 2020 | → |
| Innovations in 3-Dimensional Tissue Models of Human Brain Physiology and Diseases. | Lovett ML et al. | — | 2020 | → |
| Integrating CRISPR Engineering and hiPSC-Derived 2D Disease Modeling Systems. | Rehbach K et al. | — | 2020 | → |
| iPSC modeling of rare pediatric disorders. | Freel BA et al. | — | 2020 | → |
| Laminin 511 Precoating Promotes the Functional Recovery of Transplanted Corneal Endothelial Cells. | Zhao C et al. | — | 2020 | → |
| Leveraging preclinical models for the development of Alzheimer disease therapeutics. | Scearce-Levie K et al. | — | 2020 | → |
| Massively parallel techniques for cataloguing the regulome of the human brain. | Townsley KG et al. | — | 2020 | → |
| Microglia: Agents of the CNS Pro-Inflammatory Response. | Rodríguez-Gómez JA et al. | — | 2020 | → |
| Microglia Diversity in Health and Multiple Sclerosis. | Zia S et al. | — | 2020 | → |
| Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. | Dumas AA et al. | — | 2020 | → |
| Microphysiological Systems: A Pathologist's Perspective. | Sura R et al. | — | 2020 | → |
| Midbrain Organoids: A New Tool to Investigate Parkinson's Disease. | Smits LM et al. | — | 2020 | → |
| Modeling Alzheimer's disease with iPSC-derived brain cells. | Penney J et al. | — | 2020 | → |
| Modeling Brain Disorders Using Induced Pluripotent Stem Cells. | Vadodaria KC et al. | — | 2020 | → |
| Modeling HIV-1 neuropathogenesis using three-dimensional human brain organoids (hBORGs) with HIV-1 infected microglia. | Dos Reis RS et al. | — | 2020 | → |
| Modeling Psychiatric Disorder Biology with Stem Cells. | Das D et al. | — | 2020 | → |
| Modeling the complex genetic architectures of brain disease. | Fernando MB et al. | — | 2020 | → |
| Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease. | Serneels L et al. | — | 2020 | → |
| Modelling multiple sclerosis using induced pluripotent stem cells. | Martínez-Larrosa J et al. | — | 2020 | → |
| Multi-omic comparison of Alzheimer's variants in human ESC-derived microglia reveals convergence at APOE. | Liu T et al. | — | 2020 | → |
| Neurodegeneration in a dish: advancing human stem-cell-based models of Alzheimer's disease. | Klimmt J et al. | — | 2020 | → |
| Neuroinflammation and EIF2 Signaling Persist despite Antiretroviral Treatment in an hiPSC Tri-culture Model of HIV Infection. | Ryan SK et al. | — | 2020 | → |
| New Insights into Immune-Mediated Mechanisms in Parkinson's Disease. | Tan JSY et al. | — | 2020 | → |
| Organoid and Assembloid Technologies for Investigating Cellular Crosstalk in Human Brain Development and Disease. | Marton RM et al. | — | 2020 | → |
| Organoid and pluripotent stem cells in Parkinson's disease modeling: an expert view on their value to drug discovery. | Marotta N et al. | — | 2020 | → |
| Organoid Models of Glioblastoma to Study Brain Tumor Stem Cells. | Azzarelli R | — | 2020 | → |
| Organotypic Models to Study Human Glioblastoma: Studying the Beast in Its Ecosystem. | Pamies D et al. | — | 2020 | → |
| Pan-SHIP1/2 inhibitors promote microglia effector functions essential for CNS homeostasis. | Pedicone C et al. | — | 2020 | → |
| Patient-Derived Midbrain Organoids to Explore the Molecular Basis of Parkinson's Disease. | Galet B et al. | — | 2020 | → |
| Phosphoproteomics identifies microglial Siglec-F inflammatory response during neurodegeneration. | Morshed N et al. | — | 2020 | → |
| Protocol for Tri-culture of hiPSC-Derived Neurons, Astrocytes, and Microglia. | Ryan SK et al. | — | 2020 | → |
| Recent progress in translational engineered in vitro models of the central nervous system. | Nikolakopoulou P et al. | — | 2020 | → |
| Reverse engineering human brain evolution using organoid models. | Mostajo-Radji MA et al. | — | 2020 | → |
| Studying Human Neurodevelopment and Diseases Using 3D Brain Organoids. | Tian A et al. | — | 2020 | → |
| Tackling mitochondrial diversity in brain function: from animal models to human brain organoids. | Menacho C et al. | — | 2020 | → |
| The Genetic Relevance of Human Induced Pluripotent Stem Cell-Derived Microglia to Alzheimer's Disease and Major Neuropsychiatric Disorders. | Butler Iii RR et al. | — | 2020 | → |
| The influence of environment and origin on brain resident macrophages and implications for therapy. | Bennett ML et al. | — | 2020 | → |
| Therapeutic Plasticity of Neural Stem Cells. | Ottoboni L et al. | — | 2020 | → |
| TREM2 Alzheimer's variant R47H causes similar transcriptional dysregulation to knockout, yet only subtle functional phenotypes in human iPSC-derived macrophages. | Hall-Roberts H et al. | — | 2020 | → |
| Upgrading the Physiological Relevance of Human Brain Organoids. | Del Dosso A et al. | — | 2020 | → |
| Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk. | Raman S et al. | — | 2020 | → |
| Using human pluripotent stem cell models to study autism in the era of big data. | Nehme R et al. | — | 2020 | → |
| When glia meet induced pluripotent stem cells (iPSCs). | Li L et al. | — | 2020 | → |
| Alzheimer's Disease Research Using Human Microglia. | Lue LF et al. | — | 2019 | → |
| Alzheimer's in a dish - induced pluripotent stem cell-based disease modeling. | de Leeuw S et al. | — | 2019 | → |
| ApoE4-Induced Cholesterol Dysregulation and Its Brain Cell Type-Specific Implications in the Pathogenesis of Alzheimer's Disease. | Jeong W et al. | — | 2019 | → |
| Astrocytes and microglia: Models and tools. | Guttenplan KA et al. | — | 2019 | → |
| Attenuation of neuroinflammation reverses Adriamycin-induced cognitive impairments. | Allen BD et al. | — | 2019 | → |
| Biologically inspired approaches to enhance human organoid complexity. | Holloway EM et al. | — | 2019 | → |
| Brain organoids: advances, applications and challenges. | Qian X et al. | — | 2019 | → |
| Brain Organoids as Tools for Modeling Human Neurodevelopmental Disorders. | Adams JW et al. | — | 2019 | → |
| Concise Review: Modeling Neurodegenerative Diseases with Human Pluripotent Stem Cell-Derived Microglia. | Haenseler W et al. | — | 2019 | → |
| Constructing and Deconstructing Cancers using Human Pluripotent Stem Cells and Organoids. | Smith RC et al. | — | 2019 | → |
| Development of a Chimeric Model to Study and Manipulate Human Microglia In Vivo. | Hasselmann J et al. | — | 2019 | → |
| Differentiation of Human-Induced Pluripotent Stem Cells to Macrophages for Disease Modeling and Functional Genomics. | Shi J et al. | — | 2019 | → |
| Drug discovery in psychopharmacology: from 2D models to cerebral organoids . | Rossetti AC et al. | — | 2019 | → |
| Enforced microglial depletion and repopulation as a promising strategy for the treatment of neurological disorders. | Han J et al. | — | 2019 | → |
| Functionalization of Brain Region-specific Spheroids with Isogenic Microglia-like Cells. | Song L et al. | — | 2019 | → |
| Generating microglia from human pluripotent stem cells: novel in vitro models for the study of neurodegeneration. | Speicher AM et al. | — | 2019 | → |
| Glial regulation of synapse maturation and stabilization in the developing nervous system. | Van Horn MR et al. | — | 2019 | → |
| Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. | Golde TE | — | 2019 | → |
| Human Glial Chimeric Mice to Define the Role of Glial Pathology in Human Disease. | Mariani JN et al. | — | 2019 | → |
| Human Induced Pluripotent Stem Cells : Clinical Significance and Applications in Neurologic Diseases. | Chang EA et al. | — | 2019 | → |
| Human Interleukin-34 facilitates microglia-like cell differentiation and persistent HIV-1 infection in humanized mice. | Mathews S et al. | — | 2019 | → |
| Human iPSC application in Alzheimer's disease and Tau-related neurodegenerative diseases. | Tcw J | — | 2019 | → |
| Human iPSC-derived microglia assume a primary microglia-like state after transplantation into the neonatal mouse brain. | Svoboda DS et al. | — | 2019 | → |
| Human organoids: a new dimension in cell biology. | Lehmann R et al. | — | 2019 | → |
| Human stem cell-derived monocytes and microglia-like cells reveal impaired amyloid plaque clearance upon heterozygous or homozygous loss of TREM2. | Claes C et al. | — | 2019 | → |
| Immune Signaling in Neurodegeneration. | Hammond TR et al. | — | 2019 | → |
| Important advances in Alzheimer's disease from the use of induced pluripotent stem cells. | Majolo F et al. | — | 2019 | → |
| Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. | Sellgren CM et al. | — | 2019 | → |
| Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis. | Liu S et al. | — | 2019 | → |
| Microglia as Dynamic Cellular Mediators of Brain Function. | Wright-Jin EC et al. | — | 2019 | → |
| Microglia as possible therapeutic targets for autism spectrum disorders. | Andoh M et al. | — | 2019 | → |
| Microglia Biology: One Century of Evolving Concepts. | Prinz M et al. | — | 2019 | → |
| Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities. | Hemonnot AL et al. | — | 2019 | → |
| Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk. | McQuade A et al. | — | 2019 | → |
| Modeling Alzheimer's disease with human iPS cells: advancements, lessons, and applications. | Essayan-Perez S et al. | — | 2019 | → |
| Modeling Brain Somatic Mosaicism With Cerebral Organoids, Including a Note on Mutant Microglia. | Verheijen BM | — | 2019 | → |
| Modeling Cell-Cell Interactions in Parkinson's Disease Using Human Stem Cell-Based Models. | Simmnacher K et al. | — | 2019 | → |
| Modeling cell-cell interactions in the brain using cerebral organoids. | Oliveira B et al. | — | 2019 | → |
| Modeling Polyglutamine Expansion Diseases with Induced Pluripotent Stem Cells. | Naphade S et al. | — | 2019 | → |
| Nanostructured Modulators of Neuroglia. | Maysinger D et al. | — | 2019 | → |
| Neurosteroids as regulators of neuroinflammation. | Yilmaz C et al. | — | 2019 | → |
| New Challenges of HIV-1 Infection: How HIV-1 Attacks and Resides in the Central Nervous System. | Rojas-Celis V et al. | — | 2019 | → |
| Pathological Changes in Alzheimer's Disease Analyzed Using Induced Pluripotent Stem Cell-Derived Human Microglia-Like Cells. | Xu M et al. | — | 2019 | → |
| Phagocytosis in the Brain: Homeostasis and Disease. | Galloway DA et al. | — | 2019 | → |
| PSEN1ΔE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. | Konttinen H et al. | — | 2019 | → |
| Re-thinking the Etiological Framework of Neurodegeneration. | Castillo X et al. | — | 2019 | → |
| Role of Microglia in Ataxias. | Ferro A et al. | — | 2019 | → |
| Special issue on stem cell and tissue engineering in development, disease, and repair. | Shcheglovitov A et al. | — | 2019 | → |
| Stem-cell-derived human microglia transplanted in mouse brain to study human disease. | Mancuso R et al. | — | 2019 | → |
| Studying Heterotypic Cell⁻Cell Interactions in the Human Brain Using Pluripotent Stem Cell Models for Neurodegeneration. | Song L et al. | — | 2019 | → |
| Studying Human Neurological Disorders Using Induced Pluripotent Stem Cells: From 2D Monolayer to 3D Organoid and Blood Brain Barrier Models. | Logan S et al. | — | 2019 | → |
| The complexity of tau in Alzheimer's disease. | Naseri NN et al. | — | 2019 | → |
| The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer's Disease. | Zhong L et al. | — | 2019 | → |
| The involvement of microglia in Alzheimer's disease: a new dog in the fight. | Moore Z et al. | — | 2019 | → |
| The pro-remyelination properties of microglia in the central nervous system. | Lloyd AF et al. | — | 2019 | → |
| The role of sleep deprivation and circadian rhythm disruption as risk factors of Alzheimer's disease. | Wu H et al. | — | 2019 | → |
| Transcriptional and Epigenetic Regulation of Microglia in Health and Disease. | Yeh H et al. | — | 2019 | → |
| Transcriptional regulation of homeostatic and disease-associated-microglial genes by IRF1, LXRβ, and CEBPα. | Gao T et al. | — | 2019 | → |
| Understanding and Modulating Immunity With Cell Reprogramming. | Pires CF et al. | — | 2019 | → |
| Use of human pluripotent stem cell-derived cells for neurodegenerative disease modeling and drug screening platform. | Garcia-Leon JA et al. | — | 2019 | → |
| 2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. | Centeno EGZ et al. | — | 2018 | → |
| 3D human brain cell models: New frontiers in disease understanding and drug discovery for neurodegenerative diseases. | Korhonen P et al. | — | 2018 | → |
| A Combination of Ontogeny and CNS Environment Establishes Microglial Identity. | Bennett FC et al. | — | 2018 | → |
| An Overview of <i>in vitro</i> Methods to Study Microglia. | Timmerman R et al. | — | 2018 | → |
| Astrocyte EV-Induced lincRNA-Cox2 Regulates Microglial Phagocytosis: Implications for Morphine-Mediated Neurodegeneration. | Hu G et al. | — | 2018 | → |
| A transcriptomic atlas of aged human microglia. | Olah M et al. | — | 2018 | → |
| Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons. | Engle SJ et al. | — | 2018 | → |
| Bone-Marrow-Derived Microglia-Like Cells Ameliorate Brain Amyloid Pathology and Cognitive Impairment in a Mouse Model of Alzheimer's Disease. | Kawanishi S et al. | — | 2018 | → |
| Brain Organoids and the Study of Neurodevelopment. | Trujillo CA et al. | — | 2018 | → |
| Brain organoids as models to study human neocortex development and evolution. | Heide M et al. | — | 2018 | → |
| Building Models of Brain Disorders with Three-Dimensional Organoids. | Amin ND et al. | — | 2018 | → |
| Cortical organoids: why all this hype? | Marsoner F et al. | — | 2018 | → |
| Development and disease in a dish: the epigenetics of neurodevelopmental disorders. | Lewis EM et al. | — | 2018 | → |
| Development and validation of a simplified method to generate human microglia from pluripotent stem cells. | McQuade A et al. | — | 2018 | → |
| Differentiation of Glial Cells From hiPSCs: Potential Applications in Neurological Diseases and Cell Replacement Therapy. | Zheng W et al. | — | 2018 | → |
| Elucidating the Interactive Roles of Glia in Alzheimer's Disease Using Established and Newly Developed Experimental Models. | Chun H et al. | — | 2018 | → |
| Functional Studies of Missense TREM2 Mutations in Human Stem Cell-Derived Microglia. | Brownjohn PW et al. | — | 2018 | → |
| Generating tissue-resident macrophages from pluripotent stem cells: Lessons learned from microglia. | Claes C et al. | — | 2018 | → |
| Generation of defined neural populations from pluripotent stem cells. | McComish SF et al. | — | 2018 | → |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | — | 2018 | → |
| Genome engineering for CNS injury and disease. | Pardieck J et al. | — | 2018 | → |
| Human fibroblast and stem cell resource from the Dominantly Inherited Alzheimer Network. | Karch CM et al. | — | 2018 | → |
| Identification of glia phenotype modulators based on select glial function regulatory signaling pathways. | Lee SH et al. | — | 2018 | → |
| IgM response against amyloid-beta in aging: a potential peripheral protective mechanism. | Agrawal S et al. | — | 2018 | → |
| Induced pluripotent stem cells (iPSCs) as model to study inherited defects of neurotransmission in inborn errors of metabolism. | Jung-Klawitter S et al. | — | 2018 | → |
| Induction of a Senescence-Like Phenotype in Cultured Human Fetal Microglia During HIV-1 Infection. | Chen NC et al. | — | 2018 | → |
| iPS cells in the study of PD molecular pathogenesis. | Cobb MM et al. | — | 2018 | → |
| Isolation and Phenotyping of Adult Mouse Microglial Cells. | Grabert K et al. | — | 2018 | → |
| Is Parkinson's Disease a Neurodevelopmental Disorder and Will Brain Organoids Help Us to Understand It? | Schwamborn JC | — | 2018 | → |
| Mechanisms of dietary flavonoid action in neuronal function and neuroinflammation. | Jaeger BN et al. | — | 2018 | → |
| Microglia and macrophages in brain homeostasis and disease. | Li Q et al. | — | 2018 | → |
| Microglia and the Brain: Complementary Partners in Development and Disease. | Hammond TR et al. | — | 2018 | → |
| Microglia in Alzheimer's Disease: A Role for Ion Channels. | Thei L et al. | — | 2018 | → |
| Microglia innately develop within cerebral organoids. | Ormel PR et al. | — | 2018 | → |
| Microglia in neurodegeneration. | Hickman S et al. | — | 2018 | → |
| Microglial immune checkpoint mechanisms. | Deczkowska A et al. | — | 2018 | → |
| Microglial signatures and their role in health and disease. | Butovsky O et al. | — | 2018 | → |
| Modeling Alzheimer's disease brains in vitro. | Henstridge CM et al. | — | 2018 | → |
| Modeling Parkinson's Disease Using Patient-specific Induced Pluripotent Stem Cells. | Li H et al. | — | 2018 | → |
| Modelling glioma invasion using 3D bioprinting and scaffold-free 3D culture. | van Pel DM et al. | — | 2018 | → |
| Modelling microglial function with induced pluripotent stem cells: an update. | Pocock JM et al. | — | 2018 | → |
| Modelling Sporadic Alzheimer's Disease Using Induced Pluripotent Stem Cells. | Rowland HA et al. | — | 2018 | → |
| Organoids required! A new path to understanding human brain development and disease. | Arlotta P | — | 2018 | → |
| Representing Diversity in the Dish: Using Patient-Derived <i>in Vitro</i> Models to Recreate the Heterogeneity of Neurological Disease. | Ghaffari LT et al. | — | 2018 | → |
| Stem cell models of human synapse development and degeneration. | Wilson ES et al. | — | 2018 | → |
| Studying the Brain in a Dish: 3D Cell Culture Models of Human Brain Development and Disease. | Brown J et al. | — | 2018 | → |
| Studying tissue macrophages in vitro: are iPSC-derived cells the answer? | Lee CZW et al. | — | 2018 | → |
| Synaptic dysfunction in neurodegenerative and neurodevelopmental diseases: an overview of induced pluripotent stem-cell-based disease models. | Taoufik E et al. | — | 2018 | → |
| The G protein-coupled receptor GPR34 - The past 20 years of a grownup. | Schöneberg T et al. | — | 2018 | → |
| The Kaleidoscope of Microglial Phenotypes. | Dubbelaar ML et al. | — | 2018 | → |
| The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans. | Xiang X et al. | — | 2018 | → |
| Uncovering True Cellular Phenotypes: Using Induced Pluripotent Stem Cell-Derived Neurons to Study Early Insults in Neurodevelopmental Disorders. | Fink JJ et al. | — | 2018 | → |
| Understanding the role of steroids in typical and atypical brain development: Advantages of using a "brain in a dish" approach. | Adhya D et al. | — | 2018 | → |
| Activation of the STING-Dependent Type I Interferon Response Reduces Microglial Reactivity and Neuroinflammation. | Mathur V et al. | — | 2017 | → |
| A Highly Efficient Human Pluripotent Stem Cell Microglia Model Displays a Neuronal-Co-culture-Specific Expression Profile and Inflammatory Response. | Haenseler W et al. | — | 2017 | → |
| Complement System in Neural Synapse Elimination in Development and Disease. | Presumey J et al. | — | 2017 | → |
| Excess α-synuclein compromises phagocytosis in iPSC-derived macrophages. | Haenseler W et al. | — | 2017 | → |
| Fibromyalgia and microglial TNF-α: Translational research using human blood induced microglia-like cells. | Ohgidani M et al. | — | 2017 | → |
| Generating CNS organoids from human induced pluripotent stem cells for modeling neurological disorders. | Brawner AT et al. | — | 2017 | → |
| Human Induced Pluripotent Stem Cell-Derived Macrophages for Unraveling Human Macrophage Biology. | Zhang H et al. | — | 2017 | → |
| In Vivo Imaging of Microglial Calcium Signaling in Brain Inflammation and Injury. | Tvrdik P et al. | — | 2017 | → |
| Key Aging-Associated Alterations in Primary Microglia Response to Beta-Amyloid Stimulation. | Caldeira C et al. | — | 2017 | → |
| Microglia and Monocytes/Macrophages Polarization Reveal Novel Therapeutic Mechanism against Stroke. | Kanazawa M et al. | — | 2017 | → |
| Microglia emerge as central players in brain disease. | Salter MW et al. | — | 2017 | → |
| Modulation of Hematopoietic Lineage Specification Impacts TREM2 Expression in Microglia-Like Cells Derived From Human Stem Cells. | Amos PJ et al. | — | 2017 | → |
| On place and time: microglia in embryonic and perinatal brain development. | Thion MS et al. | — | 2017 | → |
| Prospects for Modeling Abnormal Neuronal Function in Schizophrenia Using Human Induced Pluripotent Stem Cells. | Prytkova I et al. | — | 2017 | → |
| Stem cell models of Alzheimer's disease: progress and challenges. | Arber C et al. | — | 2017 | → |
| The Importance of Non-neuronal Cell Types in hiPSC-Based Disease Modeling and Drug Screening. | Gonzalez DM et al. | — | 2017 | → |